Phase I/II Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Phase: PHASE1
Conditions: Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Splenic Mantle Cell Lymphoma
Sponsor: M.D. Anderson Cancer Center

 
 
 
 
 
 
 
 
Phase 1/2 Study of Oral ONC201 in Patients with Relapsed/Refractory
Non-Hodgkin’sLymphoma
 
 
 
 
Protocol # 2014-0630
 
 
November 13, 2018
 
 
 
 
 
 
Principal Investigator:
 
 
Michael Wang, M.D.
 
 
 
 
Co-Investigators:
 
 
Hun Lee, M.D.
 
 
 
 
 
 
 
 
 

2 
Protocol 2014-0630
November 13, 2018
 
 
 
Table of Contents
1 
BACKGROUND ................................................................................................................................................ 6 
1.1 DEFINITION AND CLINIC COURSE OF MCL ................................................................................................... 6 
1.2  DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LOW GRADE LYMPHOMA ..................................... 7 
1.3 INVESTIGATIONAL AGENT ONC201 .............................................................................................................. 7 
1.4 NONCLINICAL PHARMACOLOGY .................................................................................................................. 7 
1.5  PRECLINICAL EFFICACY ................................................................................................................................ 8 
1.6 MECHANISM OF ACTION ............................................................................................................................ 12 
1. 7 PRECLINICAL ACTIVITY .............................................................................................................................. 12 
1.7.1 IN VITRO MONOAGENT ...................................................................................................................... 12 
1.7.2  EFFECTS ON NORMAL CELLS .............................................................................................................. 13 
1.7.3 IN VIVO MONOAGENT ........................................................................................................................ 15 
1.7.4 COMBINATION THERAPY .................................................................................................................... 15 
1.8 NONCLINICAL TOXICOLOGY ....................................................................................................................... 16 
1.8.1 NON-GLP TOXICOLOGY STUDIES IN RATS ........................................................................................... 16 
1.8.2 NON-GLP TOXICOLOGY STUDIES IN DOGS .......................................................................................... 17 
1.9  GLP TOXICOLOGY AND SAFETY STUDIES ................................................................................................... 17 
1.9.1  SINGLE DOSE ORAL TOXICITY STUDY IN DOGS (GLP) ......................................................................... 17 
1.9.2 SINGLE DOSE ORAL TOXICITY STUDY IN RATS (GLP) ........................................................................... 18 
1.10 PHARMACOKINETICS ................................................................................................................................ 19 
1.10.1  PHARMACOKINETICS IN ANIMALS ................................................................................................... 19 
1.10.2  PHARMACOKINETICS IN HUMANS ................................................................................................... 19 
1.11  RESPIRATORY STUDIES ............................................................................................................................ 20 
1.12  CARDIOVASCULAR ................................................................................................................................... 21 
1.13  CENTRAL NERVOUS SYSTEM ................................................................................................................... 21 
1.13.1  RATS ................................................................................................................................................. 21 
1.13.2 DOGS ................................................................................................................................................. 21 
1.14 NONCLINICAL PHARMACOKINETICS, METABOLISM, AND DOSE SELECTION ........................................... 21 
1.15 CLINICAL STUDIES..................................................................................................................................... 23 
1.16  EFFECTS IN HUMANS ............................................................................................................................... 25 
1.17 STUDY RATIONALE...................................................................................................................................... 26 

3 
Protocol 2014-0630
November 13, 2018
 
 
2 
STUDY OBJECTIVES ....................................................................................................................................... 26 
2.1 PRIMARY OBJECTIVE OF PHASE 1 ............................................................................................................... 26 
2.2 SECONDARY OBJECTIVE OF PHASE 1 .......................................................................................................... 26 
2.3 PRIMARY OBJECTIVES OF PHASE 2 ............................................................................................................. 27 
2.4 SECONDARY OBJECTIVES OF PHASE 2 ........................................................................................................ 27 
3 
ENTRY CRITERIA ........................................................................................................................................... 28 
3.1 INCLUSION CRITERIA .................................................................................................................................. 28 
3.2 EXCLUSION CRITERIA .................................................................................................................................. 28 
4 
STUDY DESIGN AND TREATMENT SCHEDULE .............................................................................................. 29 
4.1 STUDY DESIGN ............................................................................................................................................ 29 
4.1.1 PHASE 1 ............................................................................................................................................... 29 
4.1.2 PHASE 2 ............................................................................................................................................... 30 
4.2 TREATMENT SCHEDULE ............................................................................................................................. 30 
4.3 ONC201 STUDY DRUG ADMINISTRATION .................................................................................................. 31 
4.4 DOSE LEVELS TO BE STUDIED ..................................................................................................................... 31 
4.5 DOSE ESCALATION PROCESS ...................................................................................................................... 31 
4.6 SUBJECT REPLACEMENT ............................................................................................................................. 32 
4.7 DETERMINATION OF MAXIMUM TOLERATED DOSE .................................................................................. 32 
4.7.1 MAXIMUM TOLERATED DOSE ............................................................................................................. 32 
4.7.2 DOSE LIMITING TOXICITY .................................................................................................................... 33 
5 
ONC201 STUDY DRUG SUPPLY ..................................................................................................................... 33 
5.1 DESCRIPTION ................................................................................................................................................ 33 
5.2 FORMULATION ........................................................................................................................................... 34 
5.3 SHIPPING AND STORAGE ............................................................................................................................ 34 
5.4 DRUG ACCOUNTABILITY ............................................................................................................................. 34 
6 
DOSE MODIFICATIONS AND INITIATION OF A NEW CYCLE OF THERAPY ..................................................... 35 
6.1 ONC201 DOSE REDUCTION STEPS .............................................................................................................. 35 
6.2 DOSE MODIFICATION GUIDELINES ............................................................................................................ 35 
6.3 INITIATION OF A NEW CYCLE OF THERAPY ................................................................................................ 37 
6.4 CONCOMITANT THERAPY........................................................................................................................... 37 
6.4.1 REQUIRED PREGNANCY PREVENTION ................................................................................................. 38 
6.4.2 SAFETY CONSIDERATIONS ................................................................................................................... 38 
6.5 TREATMENT COMPLIANCE ......................................................................................................................... 38 

4 
Protocol 2014-0630
November 13, 2018
 
 
6.6 DISCONTINUATION FROM TREATMENT .................................................................................................... 39 
7 
VISIT SCHEDULE AND ASSESSMENT ............................................................................................................. 39 
7.1 STUDY PROCEDURES .................................................................................................................................. 39 
7.1.1 SCREENING ASSESSMENTS .................................................................................................................. 39 
7.1.2 ON-STUDY AND END OF STUDY ASSESSMENTS .................................................................................. 40 
7.1.3 EFFICACY ASSESSMENT ....................................................................................................................... 40 
7.1.4 SAFETY ASSESSMENTS ......................................................................................................................... 40 
7.1.5 PHARMACOKINETICS ........................................................................................................................... 40 
7.1.6 ECG ASSESSMENTS .............................................................................................................................. 40 
8 
ADVERSE EVENTS ......................................................................................................................................... 43 
8.1 ADVERSE EVENTS DEFINITIONS .................................................................................................................. 43 
8.2 ADVERSE EVENT CAUSALITY ASSESSMENT ................................................................................................ 44 
8.3 SERIOUS ADVERSE EVENT REPORTING (SAE) FOR MD ANDERSON-SPONSORED IND PROTOCOLS ........... 45 
8.3.1 OTHER MALIGNANCIES ....................................................................................................................... 46 
8.4 INVESTIGATOR REPORTING RESPONSIBILITIES .......................................................................................... 46 
8.4.1 INVESTIGATOR COMMUNICATIONS WITH ONCOCEUTICS ................................................................. 46 
8.5 ADVERSE EVENT UPDATES AND IND SAFETY REPORTS .............................................................................. 48 
9 
STATISTICS ANALYSIS ................................................................................................................................... 48 
9.1 STUDY DESIGN ............................................................................................................................................ 48 
9.1.1 PHASE 1 ............................................................................................................................................... 48 
External Data Safety Monitoring Board (eDSMB) toxicity and efficacy monitoring .......................................... 50 
9.1.3 ANALYSIS PLAN .................................................................................................................................... 51 
10.1 COMPLETE RESPONSE (CR) ...................................................................................................................... 52 
10.2 PARTIAL RESPONSE (PR) ........................................................................................................................... 53 
10.3 STABLE DISEASE (SD) ................................................................................................................................ 53 
10.4 RELAPSED DISEASE (AFTER CR) /PROGRESSIVE DISEASE (AFTER PR, SD) ................................................. 54 
APPENDIX 1 ........................................................................................................................................................ 55 
APPENDIX 2 ........................................................................................................................................................ 58 
APPENDIX 3 ........................................................................................................................................................ 59 
APPENDIX 4 ........................................................................................................................................................ 60 
Appendix 7 ......................................................................................................................................................... 65 
Appendix 8 ......................................................................................................................................................... 66 
Appendix 9 ......................................................................................................................................................... 67 

5 
Protocol 2014-0630
November 13, 2018
 
 
Appendix 10 ....................................................................................................................................................... 68 
Appendix 11  Body Surface Area Assessment Note ........................................................................................... 69 
Appendix 12 CTCL Assessment and Response ................................................................................................... 70 
APPENDIX 13 ...................................................................................................................................................... 71 
11. 
REFERENCES ........................................................................................................................................... 73 
 

6 
Protocol 2014-0630
November 13, 2018
 
 
1
BACKGROUND
1.1 DEFINITION AND CLINIC COURSE OF MCL
Mantle cell lymphoma (MCL) is an aggressive and distinct type of B-cell non-Hodgkin lymphoma 
(NHL) that is relatively rare, accounting for ~4–8 % of adult NHL (Weisenburger et al., 1982). This 
disease affects primarily the elderly population, with a median age of 68 years at diagnosis, and is 
more prevalent in men and Caucasians (Zhou et al., 2008). The median overall survival in this 
setting is under 5 years, though survival has improved drastically in recent decades due to the
emergence of new therapies (Herrmann et al., 2009).
 
The World Health Organization (WHO) classifies MCL on the basis of clinical, histopathological, 
immunological, and cytogenetic or molecular data (Swerdlow et al., 2008). The genetic 
characteristic of MCL is the t(11;14)(q13;q32) translocation that juxtaposes the immunoglobulin 
heavy chain variable region (IGVH) gene on 14q32 to the CCND1 gene on 11q13, resulting in the 
overexpression of cyclin D1 (Jares et al., 2007). There is a small subset of cyclin D1-negative MCL
tumor, but they are morphologically, immunophenotypically, and by global expression profile 
indistinguishable from conventional MCL. These CCND1-negative tumors typically express SOX11 
that may be used as a diagnostic for these patients (Rosenwald et al., 2003; Salaverria et al., 2013).
 
 
MCL is treated with chemotherapy regimens that are used to treat other subtypes of lymphomas: 
alkylating agents, fludarabine, and bendamustine. Rituximab is an anti-CD20 antibody that is 
commonly combined in most regimens. A widely used regimen is the combination of rituximab plus 
fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) (Khouri
et al., 2005; Romaguera et al., 2005). This regimen resulted in a median time to treatment failure of
4.6 years, although toxicities were significant and caused ~30% of patients to discontinue therapy
prior to completing cycles. Maintenance therapy typically uses rituximab based on efficacy benefits 
observed in small studies (Forstpointner et al., 2006, Kahl et al., 2006).
 
 
After the first relapse, the prognosis is poor, with a median survival of approximately 1–2 years
(Khouri et al., 2003; Hiddemann et al., 1998). Bortezomib is a proteasome inhibitor approved by the
US FDA to treat relapsed/refractory MCL based on the data from a multicenter Phase 2 study (Fisher
et al., 2006; Goy et al., 2009). This study confirmed the single-agent activity of bortezomib in
patients with relapsed or refractory MCL who have received at least one prior therapy. The overall
response rate was 33%, including an 8% complete response (CR). The median time to progression 
was 6.7 months, and the median overall survival was 23.5 months. Recently, ibrutinib was approved
in relapsed/refractory MCL based on a response rate of 68%, with a complete response rate of 21%
and a partial response rate of 47% (Wang et al, 2013). Prior bortezomib therapy did not alter the
clinical efficacy of ibrutinib. Despite the emergence of these new treatment options, therapy
resistance is very common in MCL (Leonard et al., 2001) and additional treatment options are
needed in this setting due to the poor prognosis and difficulties with tolerating therapies in this aging
population.
 
 

7 
Protocol 2014-0630
November 13, 2018
 
 
1.2 DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LOW GRADE 
LYMPHOMA
 
Diffuse large B cell lymphomas (DLBCLs) are the most common subtype of NHL, representing 30-
40% of adult NHLs. Approximately 50-60% of patients with DLBCL maintain complete remission 
after first-line therapy. However, 30-40% relapse; 10% have refractory disease and have a poor
prognosis, with an overall survival of 3-4 months without treatment (Perry et al., 1998; Fisher et al., 
1993; Pfreundschuh et al., 2006). Prognostic factors include: time to relapse, relapsed or refractory
disease, Age Adjusted International Prognostic Factors Index, and rituximab naïve status (Vellenga 
et al., 2008; Campo et al., 2011; Kewalramani et al., 2004; Hamlin et al., 2003; Martín et al., 2008).
 
Improving survival in DLBCL is expected to require optimization of therapy in NHL, and the
identification of new therapies with compelling efficacy
and an acceptable safety
profile in
combination with other chemotherapies.
Follicular low grade lymphoma is the second most common subtype of NHL and accounts for 20% of 
NHL. Most patients present with advanced stage IV disease; although more indolent in behavior, it is 
still incurable. As quality of life becomes even more relevant in this subtype, and since current 
chemotherapy combinations carry with them known toxicity, identification of new drugs which are 
efficacious and have new mechanisms of action and a very low toxicity profile are desirable (Kahl 
BS et al. Blood. 2016)
 
1.3 INVESTIGATIONAL AGENT ONC201
 
ONC201 (TIC10) is a first-in-class small molecule that induces ER stress and inactivates the Ras 
effector target kinases, Akt and ERK, selectively in tumor, but not normal, cells to safely trigger
cancer cell death (Allen et al., 2013).
 
 
1.4 NONCLINICAL PHARMACOLOGY
 
ONC201 is a first-in-class small molecule targeted anticancer compound under development by
Oncoceutics to treat advanced cancer. ONC201 is a stable, water soluble, orally active, and blood
brain barrier-penetrable compound that has demonstrated p53-independent anticancer activity in 
many preclinical models that include glioblastoma, breast cancer, colon cancer, lung cancer,
lymphoma, and others. ONC201 kills cancer cells while sparing normal cells by inducing ER stress
and inactivating the prosurvival kinases Akt and ERK in tumor, but not normal cells, to trigger
antitumor effects such as apoptosis. In normal cells, only a partial and transient inactivation of one
of the pathways is observed that does not induce cell death. The safety profile of ONC201 in GLP
safety studies is consistent with this differential activity of ONC201 in tumor versus normal cells. 
Dual inactivation of Akt and ERK by ONC201 is sustained in tumor but not normal cells, is
maintained in the presence of upstream stimuli such as ligands or mutations, and allows for broad-
spectrum antitumor activity despite cancer cell resistance to chemotherapy, radiation, and targeted
therapy. ONC201 prolongs survival and shrinks tumors in a variety of preclinical models, including

8 
Protocol 2014-0630
November 13, 2018
 
 
highly mutated and refractory cancer patient samples and cancer cell lines in vitro and in vivo.
 
 
The profile of ONC201 is well suited for an oncology product: efficacious with infrequent 
administration, broad-spectrum activity independent of mutations, orally active, compelling safety
profile, combines synergistically and safely with many approved therapies, highly active by
employing a combination of established anti-tumor/pro-apoptotic pathways, highly stable, water
soluble, and penetrates the blood-brain barrier. The safety margin (ratio of therapeutic dose to 
lowest dose with a mild adverse event) of ONC201 is at least 10-fold in rats and dogs in GLP
toxicology studies. The efficacy of ONC201 has been consistently demonstrated in >80 in vitro
models and 16 in vivo experiments (subcutaneous, orthotopic, and transgenic) and confirmed by
multiple leading cancer research institutions.
 
1.5 PRECLINICAL EFFICACY
ONC201 induces broad-spectrum cell death in tumor cells harboring diverse mutations in genes such
as p53, KRAS, Raf, EGFR and others that render resistance to chemotherapies and targeted agents.
ONC201 induces caspase-mediated apoptosis in cancer cell lines and exhibits broad-spectrum 
cytotoxicity in vitro. ONC201 displays single agent anti-tumor effects (Figure 1.1) in subcutaneous 
and orthotopic colon cancer, subcutaneous triple negative breast cancer, subcutaneous non-small cell 
lung
cancer, subcutaneous and orthotopic
intracranial glioblastoma, and immunocompetent
lymphoma transgenic mouse models. ONC201 also cooperates extensively with paclitaxel, 
docetaxel, sorafenib, and bevacizumab.
 
 
ONC201 has demonstrated striking induction of apoptosis in ex vivo refractory cancer specimens 
harvested from patients with hematological malignancies. Compelling cytotoxic activity has been
documented MCL patient samples, including tumors with p53 mutations and resistance to standard-
of-care agents, such as the recently approved agent ibrutinib. Below reviews preclinical studies with
ONC201 in MCL that warrant the clinical evaluation of ONC201 as a novel treatment in advanced
NHL.
 

9 
Protocol 2014-0630
November 13, 2018
 
Figure 1.1. ONC201 antitumor activity in subcutaneous xenografts. Subcutaneous xenografts in athymic 
nude mice receiving a single dose of ONC201 (100 mg/kg, IP). Data shown is approximately 1 week following 
single dose administration and is relative to the tumor size on the day of administration. 
ONC201 induced potent antitumor effects in several mantle cell lymphoma models lymphoma cell
lines and patient samples (Ishizawa J. 2014). Induction of apoptosis in MCL cell lines has been
documented, which was particularly pronounced in the cell lines with mutant p53 (Figure 1.2).
Despite this observation, the activity of ONC201 in MCL cell lines was p53-independent, which is 
in accordance with prior reports in CRC and GBM (Allen et al, 2013) (Figure 1.3). Importantly, the 
compelling cytotoxicity exerted by ONC201 was not accompanied by evidence of genotoxic stress, 
which bodes well for its safety (Figure 1.4).
Figure 1.2. Induction of apoptosis by ONC201 in indicated MCL cell lines as a time course following ONC201 
treatment (5uM). (Ishizawa J and Andreeff M, unpublished data, 2014.) 

10 
Protocol 2014-0630
November 13, 2018
 
Figure 1.3. Induction of apoptosis by ONC201 in indicated MCL cell lines. The dose of ONC201 is indicated in 
the plot (72 hrs).  (Ishizawa J and Andreeff M, unpublished data, 2014.) 
Figure 1.4. YH2AX levels in MCL cell lines following treatment with ONC201 or comparator compounds. 
Drug incubation for 36 hours with ONC201 (ONC), 24 hours with Nutlin 3a (N3a), or 6 hours with doxorubicin 
(Dox) at indicated concentrations. (Ishizawa J and Andreeff M, unpublished data, 2014.) 
In addition to activity in MCL cell lines, ONC201 also has proven highly effective against primary
specimens, including induction of apoptosis in newly diagnosed as well as refractory MCL (Figure
1.5). These samples also included documentation of cytotoxic activity against blastic MCL tumors, 
which harbor mutant p53, as well as activity in ibrutinib-refractory MCL samples (Figure 1.6). The 
robust induction of apoptosis where such a clinically effective agent fails demonstrates the strong 
efficacy of the molecule, especially given the absence of bone marrow toxicity that usually plagues
this setting. The compelling in vitro data in NHL is complemented by prior studies with ONC201 in
the Eu-myc transgenic mouse models where mice develop spontaneously develop myc-driven B-cell
lymphomas. Oral ONC201 administered weekly for 4 weeks resulted in all mice surviving while on 
drug and a total extension of 4 weeks in overall survival that was statistically significant without 
apparent toxicity (Figure 1.7). These studies cumulatively indicate that ONC201 is a highly effective
monoagent in preclinical models of advanced NHL.

11 
Protocol 2014-0630
November 13, 2018
 
Figure 1.5. Induction of specific apoptosis in primary MCL samples following ONC201 treatment at indicated 
concentrations (72 hrs). P53 mutation status is indicated in the figure key. (Ishizawa J and Andreeff M, 
unpublished data, 2014.) 
Figure 1.6.  Primary refractory MCL patient sample treated with ONC201 or ibrutinib at indicated dose (72 
hrs).  (Ishizawa J and Andreeff` M, unpublished data, 2014.) 
 

12 
Protocol 2014-0630
November 13, 2018
 
Figure 1.7. ONC201 prolongs the survival of transgenic mice with lymphoma. Overall survival of Eʅ-myc 
treated once a week during weeks 9-12 with ONC201 (PO, qwk). P=.00789 determined by log-rank test 
1.6 MECHANISM OF ACTION
ONC201 directly antagonizes DRD2 to 
activate the integrated stress response (ISR) 
that attenuates protein translation and activates
ATF4, which causes induction of genes that
lead to apoptosis (Figure 1.8). ATF4 and CHOP
also downregulate Akt and ERK activity that
cooperatively induce complementary downstream
apoptotic
effects.
Studies
have
shown
that
ONC201 does not inactivate eIF2-alpha through
PERK, which is activated by ER stress. This
distinct mechanism may explain the lack of cross-
resistance between ONC201 and other ER stress-
inducing agents such as bortezomib. In addition,
ONC201
has
enhanced antitumor
efficacy
in
combination
with
bortezomib that
may
be
explained by engaging parallel stimuli that lead to
an enhanced activation of the ISR in tumor cells.
This mechanism of action explains the
pronounced sensitivity of ONC201 in B cell malignancies that are particularly sensitive to the 
integrated stress response.
1. 7 PRECLINICAL ACTIVITY 
1.7.1 IN VITRO MONOAGENT
ONC201 caused a dose-dependent decrease in the cell viability and colony formation capacity of 
human cancer cell lines. ONC201 induced Sub-G1 content in the TRAIL-sensitive HCT116 cells at 
Figure  1.8 Proposed  model  of  
ONC201  in tumor cells. 
 

13 
Protocol 2014-0630
November 13, 2018
 
 
5-10 ȝ0 doses in a p53-independent and Bax-dependent manner as expected. The in vitro activity 
of ONC201 was confirmed in a variety of solid human tumor cell lines that represented breast, 
colon, liver, ovarian, and prostate cancer with consistent activity observed in the 2-5 ȝ0 range).
This potency in cell-based assays is comparable to a majority of FDA-approved target anticancer
agents such as sorafenib, sunitinib, lapatinib, nilotinib, gefitinib, erlotinib, and imatinib. ONC201 
had similar in vitro activity in a panel of lymphoma cell lines representing Burkitt’s lymphoma, non-
Hodgkin’s lymphoma, mantle cell lymphoma, leukemic mantle cell lymphoma, and centroblastic 
diffuse lymphoma.
 
In addition to observing reduction in cancer cell viability, ONC201 induced apoptosis in several
human cancer cell lines. ONC201 caused a large increase in the amount of markers of apoptosis 
such as Sub-G1 content, cleaved caspase-3, and blockade of Sub-G1 with zVAD-fmk in several
cancer cell lines. zVAD-fmk is a pan-caspase apoptosis inhibitor that functions by binding to the
active site in caspases that carry out proteolysis by mimicking its substrate.
ONC201 demonstrated p53-independent activity in human GBM cell lines in the low micromolar
range. ONC201 exerted a strong cytotoxic effect, unlike temozolomide, against tumor cells isolated
from a freshly resected GBM with an oligodendroglial component that was previously resected and
irradiated. Corroborating observations by external investigators have demonstrated the compelling
monoagent efficacy of ONC201 in radio- and chemo-resistant GBM cell lines and 3D neurosphere
cultures.
Examples of other compelling efficacy studies from external investigators include
monoagent activity in refractory blastic mantle cell lymphoma patient samples, vemurafenib- resistant 
melanoma, and head and neck squamous cell carcinoma.
1.7.2 EFFECTS ON NORMAL CELLS
 
ONC201 does not highly impact the cell cycle profile or gross culture of normal human fibroblasts at
doses that induce cell death in human cancer cells. ONC201 treatment eradicated the cancer cell 
population while sparing the normal cells in a co-culture experiment. Comparing ONC201 dose-
response relationships between tumor and normal cell lines revealed a similar inflection point at
~5μM that subsequently saturated in all tested cell lines. However, ONC201 saturated efficacy at
a much lower level (<25% reduction in cell viability) than observed in normal cells (>70%). This
observation was in contrast to the positive control, doxorubicin, which results in massive cell death 
of normal cells. To ascertain if this reduction in cell viability was associated with a reduction in 
proliferation or an increase in cell death, we investigated cell cycle profiles of normal cells. ONC201
treatment did not cause any appreciable levels of cell death in normal cells, but drastically increased
cell death in tumor cells (Figure 1.9).
 

14 
Protocol 2014-0630
November 13, 2018
 
Figure 1.9. ONC201 effects on proliferation and cell death in normal and tumor cells. Cell viability of normal 
and tumor cell lines following ONC201 treatment for 72 hr (10 uM, n=3).
With the observation that ONC201 slightly reduces cell viability in normal cells, we next assayed
whether this was a transient phenomenon. We found that removing ONC201 at the end of a 72-hour 
incubation period resulted in a time-dependent complete recovery that was evident 24 hours later.
This is promising as ONC201 is largely cleared from the body in rats and dogs within 24 hours. We 
investigated the possibility that the difference between tumor and normal cells is simply a function
of proliferation. Examining this relationship revealed no obvious correlation between the ability of 
ONC201 to reduce cell viability and the doubling rate of the cell line. These results suggest that 
ONC201 induces cell death in tumor but not normal cells; that ONC201 can cause a slight reduction 
in normal cell proliferation that is transient and reversible; and, that ONC201 activity does not 
appear to be overtly related to proliferation rate.
ONC201 treatment results in a mild inhibition of pERK and its phosphorylation site on Foxo3a 
(S294) in WI-38 normal fibroblasts. A very slight effect on Akt phosphorylation was noted, though 
this did not correlate with changes in Foxo3a S253 phosphorylation under these conditions, which is
the site on Fox3a that is phosphorylated by Akt. In HFF cells, ONC201 results in decreased pAkt 
but not pERK, with similar observations on their respective Foxo3a phosphorylation sites. ONC201 
upregulates surface TRAIL in tumor and normal cells, though to a lesser magnitude in normal cells. 
Interestingly, DR5 induction was absent in normal fibroblasts as opposed to tumor cells that boosted
production of the death receptor in response to ONC201. Doxorubicin was also capable of boosting 
surface TRAIL as well as DR5 proteins at similar magnitudes in tumor and in normal cells, 
demonstrating no appreciable differential activity between tumor and normal cells. Investigating the 
effects of ONC201 and doxorubicin on surface TRAIL and DR5 in other normal fibroblasts
confirmed these observations. A slight induction over basal levels of DR5 in ONC201-treated WI-
38 cells was observed, although the increased levels were much lower than induction by doxorubicin 
treatment. These results suggest that the therapeutic index associated with ONC201 is likely due to 
the general absence of DR5 induction as well as absence of dual Akt/MEK inactivation in normal

15 
Protocol 2014-0630
November 13, 2018
 
 
cells.
1.7.3 IN VIVO MONOAGENT
 
The efficacy of ONC201 has been evaluated in a number of different preclinical cancer models
representing diverse tumor types and oncogenic mutations. Antitumor effects were demonstrated in 
12 subcutaneous xenografts, one orthotopic xenograft, and one transgenic model. The majority of
these experiments were performed with single oral doses of ONC201. These experiments support
the conclusion that ONC201 is an effective antitumor agent in multiple preclinical cancer models 
with infrequent dosing. The activity of oral ONC201 was evaluated in the Eu-myc transgenic 
model that spontaneously develops myc-driven lymphomas at approximately Week 9 of age. Weekly
oral administration of ONC201 from Weeks 9-12 of age prolonged the median survival of the mice
by 4 weeks.  No mice died during the course of treatment or displayed signs of toxicity.
1.7.4 COMBINATION THERAPY
 
A screen was conducted that combined ONC201 with FDA-approved small molecules (NCI DTP
Approved Set IV) used in oncology in a panel of cancer cell lines representing a diverse array of 
solid tumors (brain, breast, colon, liver, lung, ovarian). Several approved oncology drugs of diverse
drug classes synergized with ONC201 under particular conditions in the screen. Notable exceptions 
were the lack of synergy observed with any mTOR or EGFR/MAPK signaling inhibitors. This
observation is in accordance with the previous report on ONC201 (Allen et al., 2013) that
demonstrates the inhibition of Akt and MAPK signaling following ONC201 monoagent treatment. 
Lack of synergy with anti-angiogenic agents were also noted, which is expected, as angiogenesis is
not represented in standard cell culture models.
 
Nine approved oncology drugs were identified for validation based on the amount of synergy and the 
number of instances of synergy observed in the screen: azacitidine (cytidine analogue); bortezomib 
(proteasome inhibitor); dacarbazine (alkylating agent); hydroxyurea
(nucleotide metabolism 
inhibitor); pralatrexate (antifolate); romidepsin (HDAC inhibitor); sorafenib (multi-kinase inhibitor);
topotecan (anti-microtubule); and vismodegib (SMO inhibitor). We evaluated the combinatorial 
activity of these agents with ONC201 in multi-dose cell viability assays in the cell lines where
synergy was previously demonstrated. The combination of ONC201 with these agents generally
results in a complete elimination of tumor cells at the higher tested doses. The validation results
were prioritized as a function of synergistic activity as well as efficacy. Six of the nine validated
agents met the prioritization criteria of imparting >20% increased reduction in cell viability over the
expected observations and a >25% reduction in absolute cell viability with the combination: 
azacitidine; bortezomib; dacarbazine; hydroxyurea; sorafenib; and vismodegib. Sorafenib possessed
 
the highest number of data points in the validation data set that met our prioritization criteria,
demonstrating synergy in HCT116 and A172 cell lines at multiple doses.
 
The combination of ONC201 and sorafenib had a cooperative effective on induction on TRAIL and
DR5 in HepG2 human hepatocellular carcinoma cells. Sorafenib also may synergize with ONC201
due to its impact on several regulators of apoptosis. Among IAP and Bcl-2 family members, 

16 
Protocol 2014-0630
November 13, 2018
 
 
sorafenib downregulates expression of survivin and XIAP in HepG2 cells. Sorafenib also negatively
regulated Mcl-1, Bax, Bak, cIAP1, and survivin in HCT116 cells that undergo apoptosis in response 
to ONC201 treatment. In vivo, ONC201 and sorafenib cooperated to yield complete tumor 
regressions in HepG2 subcutaneous xenografts.
 
1.8 NONCLINICAL TOXICOLOGY
 
In rats and dogs ONC201 was better tolerated when administered orally compared to intravenously.
In rat non-GLP studies, the No-Observed Adverse Effect Level (NOAEL) was 225 mg/kg with oral
administration compared to 100 mg/kg with a 2 hour infusion and 50 mg/kg with a 30 minutes
infusion. Non-GLP clinical observations in rodents included decreased activity, altered gait, and
mortality. In dog non-GLP studies, the NOAEL in doses was at least 120 mg/kg with oral
administration and clinical observations were limited to emesis and changes in fecal consistency.
The non-GLP studies only evaluated at clinical observations, weight gain, food consumption and
gross findings at necropsy. In general the toxicology/safety studies indicate that the acute toxicities
associated with ONC201 are limited to the day of administration and are reversible.
 
In GLP dog studies, the NOAEL was at least 42 mg/kg. Observations were limited to decreased
activity, decreased food consumption, emesis, salivation, and/or soft, loose or mucous feces. In rat
GLP studies, the NOAEL was at least 125 mg/kg. Observations included decreased activity, decreased
food consumption, decreased body weight, and abnormal stance and gait. Minor changes in serum
chemistries were noted, largely in the 225 mg/kg rats, which included slight increases in cholesterol
and chloride. The significance of these findings is unknown as other clinical chemistry and histology
did not corroborate this observation (e.g., liver findings). Rats receiving 125 or 225 mg/kg ONC201
had mild edema and inflammation that was primarily submucosal in the stomach and was
completely resolved by Day 19.
 
1.8.1 NON-GLP TOXICOLOGY STUDIES IN RATS
 
The ability of rats to tolerate ONC201 by intravenous was explored as a function of infusion time.
Clinical observations with intravenous administration included decreased activity, salivation, 
abnormal gait and stance, labored respiration, pale skin, nasal discharge, prostration during the dose,
mild body twitching, and red discharge from the mouth.
 
The NOAEL following administration of ONC201 to Sprague-Dawley rats by a 30-minute
intravenous infusion was 50 mg/kg. The NOAEL following administration of ONC201 to Sprague-
Dawley rats by a 2-hour intravenous infusion was 100 mg/kg.
Administration of 100  mg/kg
 
ONC201 by intravenous infusion over 30 minutes resulted in the death of one male rat. 
Administration of 200 mg/kg ONC201 by a 2-hour infusion resulted in the death of both animals 
during the infusion period. Following these observations, the tolerance of oral ONC201 was explored
given the potential to lower acute toxicity by lowering Cmax. Clinical observations with oral
exaggerated doses of ONC201 included decreased activity, abnormal gait and stance, prostration,
irregular respiration, moderate twitching, red discharge on the muzzle, scant feces, hunched

17 
Protocol 2014-0630
November 13, 2018
 
 
posture, not eating, pilerection, and skin cold to touch. The NOAEL following administration of
ONC201 to Sprague-Dawley rats by oral gavage was 225 mg/kg.
 
1.8.2 NON-GLP TOXICOLOGY STUDIES IN DOGS
 
In parallel to non-GLP toxicology studies in rats, the ability of beagle dogs to tolerate ONC201 was
explored. No deaths were observed at any doses in dogs. The NOAEL following the 30-minute 
intravenous infusion of ONC201 to beagle dogs is considered to be at least 33.3 mg/kg. The 2 hour-
intravenous infusion of 16.7 mg/kg ONC201 was not associated with any clinical signs of toxicity.
Therefore the NOAEL following a 2 hour-intravenous infusion of ONC201 to beagle dogs is 
considered to be greater than 16.7 mg/kg, though higher doses were not explored as the oral route 
was selected for further development based on observations in rats. The NOAEL with oral ONC201
was considered to be at least 120 mg/kg in dogs. Clinical observations at doses of 66.7 to 120 mg/kg
were limited to emesis and changes in fecal consistency.
 
1.9 GLP TOXICOLOGY AND SAFETY STUDIES
1.9.1 SINGLE DOSE ORAL TOXICITY STUDY IN DOGS (GLP)
 
A GLP study was performed to evaluate the toxicity and toxicokinetics of ONC201 following a
single oral dose to Beagle dogs followed by a 2-day or an 18-day recovery period. Dogs received a
single dose of 0, 4.2, 42, or 120 mg/kg by oral gavage. There was no mortality observed in this 
study. There were no definitive ONC201-related effects on group mean body weight or body weight
gain, ECG rhythm or morphology, mean heart rate or arterial blood pressure, urinalysis, hematology 
parameters, coagulation parameters, clinical chemistry parameters, erythrocyte morphology, gross
findings on necropsy, changes in absolute or organ to body or organ to brain weights.
 
 
Although not statistically significant, there were some dose-related decreases in group mean food
consumption for the first week following dosing. The 120 mg/kg females had statistically
significantly decreased group mean food consumption compared to the vehicle control group on
Days 14, 15 and 18. There were no clinical signs of toxicity noted following a single dose of 4.2
mg/kg ONC201. At a dose of 42 mg/kg and 120 mg/kg, some dogs had clinical observations at
approximately 1 hour post-dose including decreased activity, emesis, salivation, and/or soft, loose or 
mucous feces. Of uncertain relationship to ONC201 administration was the unusual finding of 
mononuclear cell inflammation in the blood vessels of the brain, which was multifocal and mild in 
one high dose female at Day 3, multifocal and minimal in one high dose female at Day 19, and
minimal and focal in one control female at Day 19. Similar findings were not noted in any male
animal.
Based on the results of this study, the NOAEL following oral administration of ONC201 at single
doses of 4.2, 42 or 120 mg/kg to Beagle dogs is considered to be at least 42 mg/kg.
 
 

18 
Protocol 2014-0630
November 13, 2018
 
 
1.9.2 SINGLE DOSE ORAL TOXICITY STUDY IN RATS (GLP)
 
Single Dose Oral Toxicity and Toxicokinetic Study in Rats with a 19-Day Recovery and a 30-
Minute Intravenous Infusion Toxicokinetic Arm (GLP)
A GLP study was performed to evaluate the toxicity of ONC201 following a single oral dose in
Sprague-Dawley rats with necropsy after a 2-day or an 18-day recovery period. Rats received 0,
12.5, 125, or 125 mg/kg ONC201 by oral gavage.
 
There was no mortality observed in this study. There were no definitive ONC201-related effects on 
coagulation parameters, clinical chemistry parameters, or gross findings at necropsy. There were no
clinical signs of toxicity noted at single doses up to 125 mg/kg ONC201. There were no ONC201-
related statistically significant changes in hematology parameters or clinical chemistries outside of 
the historical control range for these values.
 
At a dose of 225 mg/kg, clinical signs of toxicity were limited on the day of dose administration to
one out of twenty males and one out of twenty females that showed signs of decreased activity and
abnormal gait and stance. The male was also noted to have increased respiration. All were normal 
by Day 2. No ONC201 related changes were noted during the functional observational battery (CNS
activity) performed on Day 1 between 1 and 2 hr post-dose with the exception of one 225 mg/kg
female noted as having decreased activity. A statistically significant decrease in group mean body
weight gain was noted on Day 7 for the 225 mg/kg males. A statistically significant decrease in 
group mean food consumption was noted on Day 7 for the 225 mg/kg males.
 
On Day 3, the 225 mg/kg females also had increased glucose, cholesterol, sodium and chloride.
Sodium and chloride were statistically significantly increased for the 125 mg/kg females. Only
cholesterol and chloride were outside historical control ranges for this laboratory on Day 19. As the 
increase in cholesterol was only noted for the females and no corresponding liver findings were
observed, the significance of this finding is unknown. Though within normal historical control 
values for these laboratories, chloride remained increased for the 225 mg/kg males while cholesterol
remained increased for the 225 mg/kg females.
 
Changes in brain and liver weights were noted but did not occur in a dose-dependent manner and no
microscopic changes were noted for in these organs for the high dose females. These changes were
considered incidental and unrelated to treatment. At the Day 3 necropsy, ONC201-related minimal
to mild edema and/or mixed cell inflammation was present in the non-glandular stomach of 225
mg/kg males and females. This edema and inflammation was primarily submucosal, although in
some animals the inflammation involved the serosa or mesentery. Two males and one female had
minimal focal ulceration of the overlying squamous epithelium. Similar stomach findings were
seen in 125 mg/kg animals, with a lower incidence than in 225 mg/kg. There was complete 
resolution of all stomach lesions at the Day 19 necropsy, indicating full recovery.
 
Based on the results of this study, the NOAEL following oral administration of ONC201 at single
doses of 12.5, 125 or 225 mg/kg to Sprague-Dawley rats is considered to be at least 125 mg/kg.
 

19 
Protocol 2014-0630
November 13, 2018
 
 
 
Evaluation of the Effect of ONC201 Dihydrochloride on Respiratory Function following Single-
Dose Administration in Rats (GLP)
 
A GLP study was performed to determine the potential effects of ONC201 dihydrochloride on 
respiratory function in rats following a single oral gavage administration. Twenty four (6/group)
male rats received 0, 12.5, 125, or 225 mg/kg ONC201 by oral gavage and were monitored in 
plethysmographic chambers. The oral administration of ONC201 dihydrochloride at 12.5 and 125 
mg/kg did not induce any biologically relevant effects on respiratory rate, tidal volume or minute
volume in conscious male rats. A marginal to moderate transient decrease in respiratory rate and 
minute volume was observed following the oral administration of ONC201 dihydrochloride at 225
mg/kg, which resolved by 2 hours.
1.10 PHARMACOKINETICS
1.10.1 PHARMACOKINETICS IN ANIMALS
The measured half-life of ONC201 in mice is ~6 hours with intravenous administration as measured
by an HPLC-UV assay. In rats, exposure to ONC201 was dose-dependent and approximately dose-
proportional. Exposure to ONC201 was slightly greater in female rats after a single oral gavage
dose. Plasma T1/2,e ranged from 2.3 to 8.4 hours in 7 of 8 profiles. Clearance ranged from 7.5 to
23.5 L/hr/kg in 7 of 8 profiles. Volume of distribution ranged from ~49 to ~103 L/kg in 6 of 8
profiles.
 
In dogs, exposure to ONC201 following oral gavage dosing at 4.2, 42, and 120 mg/kg ONC201 was
dose-dependent and increased with greater ONC201 dose levels. Exposure to ONC201 was similar
in male and female dogs with the observation that all mean male Cmax and AUC values were
slightly greater than those corresponding female values. Elimination of ONC201 from plasma was
similar between the mid and high dose levels; mean T1/2,e ranged from 4.6 to 7.8 hours. Mean 
T1/2,e following the low dose of 4.2 mg/kg was ~1 hour [the half-life determined for dogs in the low 
dose group may represent more of a distribution phase half-life rather than the terminal plasma
elimination half-life]. Overall elimination of ONC201 was greater following the low dose.
1.10.2 PHARMACOKINETICS IN HUMANS
In a phase I dose escalation clinical trial of ONC201 in advanced solid tumors, the pharmacokinetics of single
agent ONC201 was determined by LC-MS-MS analysis of plasma collected in the first cycle of therapy within
21 days of drug administration (Fig 1.10). Trends of increasing exposure with dose were consistent with dose 
proportionality. Patients receiving 625mg ONC201 exhibited a mean half-life of 11.3  hours and achieved a 
Cmax of 3.6 ug/mL (~9.3 uM), which occurred at 1.8 hours following administration (Tmax). The mean volume 
of distribution was 369 L, consistent with a large distributive volume. 
0HDQ$8&ZDVKȝJP/DQGPHDQ&/)ZDV/K*HQHUDOO\&/)ZDVREVHUYHGWREHYDULDEOHEXt
consistent across all dose groups. There were no apparent relationships between drug CL/F and patient sex and 
age. Noticeable, shallow trends were observed with patient weight and BSA. An overall increase in CL/F was 
observed as weight and BSA increased. Although a slight upward trend was observed, there was no strong 
correlation between CL/F and CLCR.

20 
Protocol 2014-0630
November 13, 2018
 
Stronger correlations were observed with the distributive volume estimate and patient weight and BSA.  A 
increase in volume of distribution was observed with increasing patient weight or BSA, as expected 
(Supplemental Figure 2G-H). Trends of decreasing exposure with increasing weight were observed in plots of 
Cmax/Dose and AUC/Dose versus patient weight. Weight normalized CL/F was plotted versus Dose 
(Supplemental Figure 2K), showing a similar trend to un-normalized CL/F. 
Figure 1.10: Mean ONC201 plasma concentrations versus time following the 
first dose of ONC201. Concentrations are shown as (A) A mean for each dose 
cohort, or (B) for individuals treated at 625 mg. Error bars indicate standard 
deviation. 
Table 1.1 ONC201 pharmacokinetic parameters determined in patients receiving 625 mg 
ONC201 (n=24).
1.11 RESPIRATORY STUDIES
A GLP study was performed to determine the potential effects of ONC201 dihydrochloride on
Cmax
Tmax
Tlag
AUClast
OZ
t1/2
AUC
VZ/F
CL/F
(ug/mL)
(h)
(h)
(h.ug/mL)
(h-1)
(h)
(h.ng/mL)
(L)
(L/h)
Mean
3.6
1.8
0.02
37.0
0.076
11.3
37.7
369
25.19
SD
2.6
0.9
0.08
41.6
0.046
5.2
41.6
193
14.22

21 
Protocol 2014-0630
November 13, 2018
 
 
respiratory function in rats following a single oral gavage administration. The oral administration of 
ONC201 dihydrochloride at 12.5 and 125 mg/kg did not induce any biologically relevant effects on
respiratory rate, tidal volume or minute volume in conscious male rats. A marginal to moderate 
transient decrease in respiratory rate and minute volume was observed following the oral
administration of ONC201 dihydrochloride at 225 mg/kg that was recovering within 1 hour of 
administration and recovered within 2 hours of administration.
 
1.12 CARDIOVASCULAR
A cardiovascular study was conducted as a component of the GLP safety dog study that included
controls and cohorts receiving a single oral dose of ONC201 (4.2, 42, 120 mg/kg). ECGs were
obtained from all animals prior to treatment initiation and on Day 1 between 2 and 4 hours post-
dose. Blood pressure was obtained from all animals prior to treatment initiation and on Day 1
between 2 and 4 hours post-dose. There were no ONC201 effects on ECG rhythm or morphology in
dogs in this study nor were there any definitive ONC201-related effects on mean heart rate or arterial 
blood pressure noted at 1 to 2 hours post-dose.
 
1.13 CENTRAL NERVOUS SYSTEM
1.13.1 RATS
Functional Observational Battery was observed prior to treatment initiation and on Day 1 between 1
and 2 hours post-dose. For clinical observations, there were no clinical signs of toxicity noted at
single doses up to 125 mg/kg ONC201. At a dose of 225 mg/kg, clinical signs of toxicity were
limited on the day of dose administration to one male and one female that showed signs of decreased
activity and abnormal gait and stance. The male was also noted to have increased respiration. All
were normal by Day 2.
 
1.13.2 DOGS
Functional Observational Battery was observed prior to treatment initiation and on Day 1 between 1
and 2 hours post-dose. Findings for the functional observational battery performed between 1 and 2
hours post-dose on Day 1 were limited to the same noted by the clinical observations. Clinical
observation for the 42 mg/kg dose group, changes in fecal excretion were noted in 3/6 males and 1/6
females, increases in secretion (salivation) were noted in 1/6 males and vomitus was noted in 3/6
males and 1/6 females. For the 120 mg/kg dose group, changes in fecal excretion were noted in 4/6
males and 3/6 females, increases in secretion (salivation) were noted in 5/6 males and 1/6 females
and vomitus was noted in 3/6 males and 4/6 females.
 
1.14 NONCLINICAL PHARMACOKINETICS, METABOLISM, AND DOSE SELECTION
The absorption, distribution, metabolism, and excretion of ONC201 in humans are unknown. The 
pharmacokinetics of ONC201 has been studied in mice, rats, and dogs. The Tmax was at 1 hour
(which was first sampling point) and the terminal half-life was 4.6 to 8.4 hours. The drug was dose 
proportional in rat. In the dog the drug was dose proportional at the two highest doses studied.
 

22 
Protocol 2014-0630
November 13, 2018
 
 
No formal metabolic or drug-drug interactions with ONC201 or any metabolites have been
performed. These studies will be performed later in the development of this agent. A literature
search revealed that ONC201 was inactive in a CYP450 screen.
 
The total exposure to ONC201 does not appear to correlate with efficacy in nonclinical studies. 
Single dose ONC201 delivered by oral administration or intraperitoneal injection caused similar
tumor stasis in a subcutaneous tumor xenograft in athymic nude mice. A single oral dose of 25
mg/kg ONC201 yielded peak efficacy in another subcutaneous xenograft model, with higher doses
yielding similar efficacy. Furthermore, the antitumor activity was equivalent in the long term
between cohort receiving the optimal dose of 25 mg/kg ONC201 once a week, twice a week, and
once every two weeks. This observation is in accordance with delayed and sustained activity of
ONC201 observed in vitro or in vivo.
 
The acute toxicity of ONC201 appears to be related to Cmax. Thus acute toxicities are readily
alleviated with oral administration or with extension of infusion time, which lowers the Cmax.
Interestingly, the acute toxicities observed with ONC201 are generally mild, transient, and occur 
within a few hours of administration, unlike the antitumor mechanism of ONC201. These 
observations strongly suggests that the acute toxicity associated with ONC201 is an off-target effect 
that occurs at higher than necessary doses, rather than being directly associated with the mechanism
that confers efficacy.
 
The short half-life of the molecule suggests that drug-drug interactions are unlikely and that
combining ONC201 with radiation or other therapies may be well tolerated and effective, based on
the prolonged biological activity of ONC201. Given the rapid systemic clearance of ONC201, drug
accumulation with ONC201 at the infrequent dosing schedule is unlikely, providing another safety
feature for the drug.
In GLP safety studies in rats and dogs with ONC201, there were no deaths or dose limiting toxicities.
In general, adverse events associated with exaggerated doses of ONC201 were mild and reversible.
The only findings that were observed in both rats and dogs were decreased activity, decreased
food consumption (weight loss only seen in rats), and salivation. Given the safety profile of this drug
and the intended indication of advance cancer patients, the benefit-risk profile is favorable and the
Sponsor believes that ONC201 warrants clinical evaluation.
 
The starting dose for the first-in-man trial was calculated following the ICH S9 Guidance Document. 
The NOAEL and calculations are given below. The start dose was selected as 125 mg based on
rounding the lowest dose, which was based on the rat NOAEL.
 

23 
Protocol 2014-0630
November 13, 2018
 
Calculation of Starting Dose
The starting dose in the Phase I trial was selected as 125 mg based on allometric scaling and
rounding the lowest NOAEL from the GLP toxicology studies, as tabulated below. Allometric 
scaling was used in these calculations, which held true when scaling between rats and dogs in GLP
toxicology studies. This dose was calculated as 1/10th of the rat NOAEL (rat 125 mg/kg and dog 42
mg/kg translates into a starting dose of 123 mg or 138 mg for a patient with a body weight of 60 kg).
1.15 CLINICAL STUDIES
The clinical safety of ONC201 has been evaluated in a Phase I clinical trial. The design was an 
open-label, dose-escalation trial of monoagent ONC201 in patients with advanced, refractory 
tumors who had exhausted or refused standard treatment options for their respective indications. 
The primary objective of this study was to determine the recommended phase II dose (RP2D) of 
ONC201 administered orally in patients with advanced cancers, as well as to evaluate the safety 
and tolerability of the drug. Secondary objectives included pharmacokinetics and 
pharmacodynamics evaluation of ONC201 and preliminary assessment of anti-tumor efficacy.
An accelerated dose escalation design was employed to reduce the number of patients treated at
potentially sub-therapeutic dose and to accelerate the determination of the recommended phase II
dose. Ten evaluable patients (aged 47-80 years) received oral ONC201 once every 3 weeks at five
dose levels ranging from 125 to 625 mg. The study design included one patient per cohort until any
patient experiences a grade 2 adverse event during the first cycle of treatment, defined as 21 days. 
Five dose levels (125 mg, 250 mg, 375 mg, 500 mg, 625 mg) were selected for the study.
Enrollment at each subsequent dose level required that all patients enrolled at the prior dose level
completed Cycle 1 dosing and were evaluated 21 days later to assess safety. 
 
On average, patients received 3.1 doses of ONC201. Nine out of ten patients completed at least 2
cycles, 4 patients completed at least four cycles, and one patient received six cycles and remains on
therapy. 625 mg was the highest dose administered and was determined to be the RP2D that
surpassed the absorption saturation threshold by two dose levels. The only adverse event during
the dose escalation phase that was possibly attributed to ONC201 was a low grade fever. No drug-
related toxicities Grade >1 were observed in any patients in this study. Explorative laboratory
studies and physical exams did not reveal any drug-related abnormalities. Similarly, cardiovascular
assessments revealed no drug-related effects. Three Medwatch reports were filed with the FDA that

24 
Protocol 2014-0630
November 13, 2018
 
 
reported events that were not attributed to the study drug.
 
Clinical and laboratory results indicated that the drug possessed biological activity in the treated
patients. Patient #3, a 72 year old with advanced clear cell endometrial (uterine) cancer had a
mixed objective response with >50% decrease in lymphadenopathy (10/11 afflicted lymph nodes 
responded) after 2 doses. Patient #4, a 62-year-old male with renal cancer and bone metastases
with debilitating pain in the clavicle experienced relief from his clavicular pain. Patient #6, a 69-
year-old patient with prostate adenocarcinoma, has received 8 doses of ONC201 and has stable
disease. Patient #8, a 71-year old colon cancer patient had stable disease for at least 12 weeks with
4 doses of ONC201.
 
A 47-year-old male with appendiceal cancer (patient #2) had CA27.29 tumor biomarker of 30 units
that was in the abnormal range, which decreased to 20 units (normal range) after 4 doses of
ONC201. Given the heterogeneity of the tumor types in the enrolled patients, no widely used
biomarker was available to uniformly assay all patient samples. Since most solid tumors express
cytokeratin-18, the serum M30 assay was selected to detect a caspase-cleaved form of cytokeratin-
18 that occurs during apoptosis. Clinical studies have demonstrated the M30 assay to be predictive
of clinical response (Demiray et al; 2006) in solid tumors. Induction of the M30 assay for apoptosis
was noted in 67% of patients treated at the RP2D with a range of 1.25- to 4-fold increase.
An expansion phase of this Phase I trial with every three week dosing enrolled 18 additional patients 
with advanced solid tumors to confirm the tolerability of the 625mg ONC201 RP2D. The only adverse 
events among the 18 patients enrolled in the expansion phase that were attributed as possibly-related to 
ONC201 were: nausea (1 patient), emesis (2 patients), and increased level of serum amylase (2 
patients). All of these adverse events were Grade 1 and reversed rapidly. Laboratory studies and 
physical exams did not reveal any drug-related abnormalities. Similarly, cardiovascular assessments 
revealed no drug-related effects.
Another arm of this study has been opened to evaluate weekly dosing. Three patients have been 
treated with 375mg ONC201 on a weekly basis and six patients have been treated with 625mg on a 
weekly basis. As of September 8, 2016, there have been no reports to the sponsor of any drug-
related adverse events in any of these patients. All three 375mg and six of the 625mg patients have 
successfully completed the DLT window (21 days). Based on these findings, the recommended 
administration schedule of ONC201 is 625mg once every week.  
Additional clinical studies of ONC201 that are active include a Phase I clinical trial in advanced solid 
tumors and multiple myeloma, a Phase I/II clinical trial in relapsed/refractory acute leukemias and 
high-risk myelodysplastic syndrome (MDS), and a Phase II clinical trial in bevacizumab-naïve 
glioblastoma multiforme (GBM). 
A clinical trial is currently being conducted at the MD Anderson Cancer Center investigating the safety 
of ONC201 in patients with acute leukemias and myelodysplastic syndrome (study #2014-0731; 

25 
Protocol 2014-0630
November 13, 2018
 
NCT02392572).  As of February 27, 2016, 3 patients have been enrolled in this study that dosed one 
patient at 125mg once every three weeks, the other patient at 250mg once every three weeks and a third 
patient at 375mg once every three weeks. There were 3 reported instances of febrile neutropenia, lung 
infection (pneumonia) and gastrointestinal disorders. None of these were attributed as drug-related by 
the Investigator. 
Study #PH-077 (NCT02609230) is a Phase I dose-escalation study of ONC201 in patients with solid 
tumors and multiple myeloma, being conducted at Fox Chase Cancer Center.  As of February 27, 2016,
5 patients have received ONC201 125mg once every 3 weeks. Patient 1 experienced an SAE that was 
initially assessed as possibly drug related (progressed from Grade 2 fatigue at baseline to Grade 3 
fatigue). The patient had brain metastases at baseline and rapid progression of underlying disease and 
associated symptoms within 2 weeks of initiating ONC201 treatment. The SAE attribution that 
triggered the initial report is under reassessment based on the evidence of progressive underlying 
disease.   
1.16 EFFECTS IN HUMANS
So far no serious side effects have been reported in patients with advanced solid tumors and 
hematological malignancies that are attributable to ONC201. Grade I adverse events that have been 
observed and reported include fever, nausea, vomiting, fatigue, and elevated serum amylase that were 
attributed as possibly-related to ONC201. One Grade II allergic reaction occurred that was managed 
with standard medications. The table below includes adverse events attributed as at least possibly-
related to ONC201 in the Phase I trial in advanced solid tumors were Grade 1 (among 28 patients). 
Side effects seen in animals included the following:
•
Nausea
•
Salivation
•
Vomiting
•
Abnormal breathing
•
Twitching
•
Abnormal walking or standing
•
Death
The effects of ONC201 on the developing human fetus are unknown. For this reason, women of

26 
Protocol 2014-0630
November 13, 2018
 
 
childbearing potential and men must agree to use adequate contraception (hormonal or barrier
method of birth control; abstinence) prior to study entry and for the duration of study participation. 
Should a woman become pregnant or suspect she is pregnant while she or her partner is participating 
in this study, she should inform her treating physician immediately. An assessment should be made
to ensure the potential benefit would justify a potential risk to the fetus.
 
It is not known whether ONC201 is excreted in breast milk. It is recommended that women do not
breastfeed during treatment with ONC201 and for 2 months after the last dose.
 
All adverse events occurring with any patient participating in any clinical trials with ONC201 must
be reported to the Sponsor, the IRB and to health authorities (e.g., FDA) as applicable. Refer to the
study protocol for definitions of AE/SAE, assessment criteria and reporting responsibilities.
1.17 STUDY RATIONALE
 
ONC201 is a first-in-class small molecule with consistent antitumor activity in difficult-to-treat 
cancers as demonstrated using in vitro, ex vivo, and in vivo models. The mechanism of action of 
ONC201 appears to involve the activation of the integrated stress response (ISR) that causes a 
downstream inactivation Akt and ERK signaling as well as induction of the pro-apoptotic TRAIL 
pathway. Malignant B cells are highly sensitive to ER stress-inducing agents that trigger the ISR such 
as proteasome inhibitors. The efficacy of ONC201 has been demonstrated in numerous solid and 
liquid tumor cell lines and patient sample that are refractory to chemotherapy and targeted therapies, 
including B cell malignancies such as mantle cell lymphoma. ONC201 is effective in tumor cells 
harboring diverse mutations in genes such as p53, KRAS, Raf, EGFR and others that render resistance 
to chemotherapy and targeted therapies. B cell malignancies have been selected for evaluation in this 
trial based on preclinical efficacy as well as the mechanism of action of ONC201 that involves 
engagement of the ISR, inactivation of Ras signaling, and induction of the TRAIL pathway that 
should be effective in these tumors based on preclinical and clinical evidence.  
2
STUDY OBJECTIVES
2.1 PRIMARY OBJECTIVE OF PHASE 1
 
•
To determine recommended Phase 2 dose for oral ONC201 in patients with 
relapsed/refractory lymphomas.
•
To
identify
toxicities
associated
with
oral
ONC201
in
patients
with 
relapsed/refractory lymphomas.
 
2.2 SECONDARY OBJECTIVE OF PHASE 1
 
•
To determine the pharmacokinetics (PK) of oral ONC201 following administration.
•
To observe the anti-tumor effects of oral ONC201, if any occur, in patients with 
relapsed/refractory lymphomas.
•
To correlate blood and tumor markers in CTCL patients (protocol PA18-0191).
 
 

27 
Protocol 2014-0630
November 13, 2018
 
 
2.3 PRIMARY OBJECTIVES OF PHASE 2
 
•
To
determine
the
objective
response
rate
to
ONC201
in
patients
with 
relapsed/refractory lymphomas. 
 
2.4 SECONDARY OBJECTIVES OF PHASE 2
 
•
Confirm tolerability of recommended Phase 2 dose.
•
Assess clinical outcomes associated with ONC201 treatment in patients with 
relapsed/refractory lymphomas.
•
Correlate clinical outcome with tumor and serum biomarkers.
•
Correlate blood and tumor markers in CTCL patients (Protocol PA18-0191)
 

28 
Protocol 2014-0630
November 13, 2018
 
 
3
ENTRY CRITERIA
 
3.1 INCLUSION CRITERIA
 
1. Phase 1 and Phase 2: Confirmed diagnosis of previously treated relapsed and/or refractory
lymphoma.  P at i en ts  wi th  C NS  l ym p h om a are in clu d ed .
2. Age 18 years at the time of signing the informed consent.
3. Patient with leukemia phase (peripheral blood involvement), CNS lymphoma (including 
CSF-only disease), non-measurable disease, gastrointestinal (GI) MCL, or bone marrow
(BM) MCL are also eligible. Gastrointestinal or bone marrow or spleen only patients are
allowable and will be analyzed separately.
4. All adverse events related to prior therapies (chemotherapy, radiotherapy, and/or surgery)
must be resolved WRGrade 1, except for alopecia.
5. Patients must be willing to receive transfusions of blood products.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less (see Appendix 
3).
7. Patients must have the following clinical laboratory values:
•
Serum creatinine < 2.0 mg/dl.
•
Serum bilirubin < 1.5 mg/dl
•
Platelet count  > 50,000/mm^3
•
Absolute neutrophil count (ANC) > 1,000/mm^3
•
Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) < 2 x upper 
limit of normal or < 5 x upper limit of normal if hepatic metastases are present.
8. Willing and able to participate in all study related procedures and therapy including 
swallowing capsules without difficulty.
9. Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy
test and must be willing to use acceptable methods of birth control during the study and for
90 days after the last dose of study treatment. Acceptable methods of birth control include 
condoms with birth control foam, birth control pills, implantable or injectable birth control, 
birth control patch, intrauterine device (IUD), or diaphragm with spermicidal gel. Male 
patients must use an effective barrier method of contraception (i.e., condoms with birth 
control foam or diaphragm with spermicidal gel) during the study and for 90 days following
the last dose of study treatment if sexually active with a female of childbearing potential. 
Contraception must be in place at least 2 weeks prior to initiating study treatment.
10. Patient must be English-speaking (MDASI completion only)
† 
 A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or
bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has
had menses at any time in the preceding 24 consecutive months).
3.2 EXCLUSION CRITERIA
1. Any serious medical condition including but not limited to, uncontrolled hypertension, 
uncontrolled diabetes mellitus, uncontrolled infection, active/symptomatic coronary artery
disease, COPD, renal failure, active hemorrhage, or psychiatric illness that, in the investigators
opinion places the patient at unacceptable risk or would prevent the subject from signing the
informed consent form.

29 
Protocol 2014-0630
November 13, 2018
 
 
2. Pregnant or breast feeding females.
3. Use
of
any
standard/experimental
anti-lymphoma
drug
therapy,
including
steroids 
(dexamethasone dose  4 mg/day or prednisone  20 mg/day), within 3 weeks of initiation of the
study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell
infusions) within 56 days of initiation of the study drug treatment. Hydroxyurea is permitted
up to 24 hours before the first dose of study drug in patients with rapidly- proliferating disease.
4. Prior allogeneic stem cell  transplant  (SCT) within 16 weeks or autologous SCT within 8 
weeks of initiation of therapy. Patients that require immunosuppressive therapy are not eligible
within 60 days of therapy.
5. History of HIV infection. Patients with active Hepatitis B infection (not including patients with
prior Hepatitis B vaccination; or positive serum Hepatitis B antibody). Hepatitis C infection
is allowed as long as there is no active disease and is cleared by GI consultation. HIV screening
is not required for this study.
6. Significant neuropathy (Grades 3–4, or Grade 2 with pain) within 14 days prior to enrollment.
7. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of
the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease,
or partial or complete bowel obstruction, or any other gastrointestinal condition that could 
interfere with the absorption and metabolism of ONC201
8. Major surgery within 4 weeks of initiation of therapy.
9. The patient has a prior or concurrent malignancy that in the opinion of the investigator,
presents a greater risk to the patient’s health and survival, than of the MCL, within the 
subsequent 6 months at the time of consent. Investigator discretion is allowed.
10. Patients with NYHA Class III and IV heart failure, myocardial infarction in the preceding 6
months, and significant conduction abnormalities, including but not limited to 2nd degree AV block 
type II, 3rd degree block, QT prolongation (QTc > 500 msec), sick sinus syndrome, ventricular
tachycardia, symptomatic bradycardia (heart rate < 50 bpm), hypotension, light headedness and
syncope. Patients with active atrial fibrillation will be excluded. The protocol excludes patients
who have within the past year had a stent and by recommendation of their cardiologist need to 
stay on anticoagulants such as warfarin equivalent vitamin K antagonist.
11. History of allergic reactions attributed to compounds of similar chemical or biologic composition 
to ONC201 or its excipients.
12. Acute infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 
days prior to initiation of study.
Active alcoholism or use of recreational drug (evaluated by history taking).
4
STUDY DESIGN AND TREATMENT SCHEDULE
 
4.1 STUDY DESIGN
 
This will be a single-center, Phase 1/2 clinical trial in patients with refractory or relapsed lymphoma.
The feasibility of administrating ONC201 and the recommended Phase 2 dose (RP2D) will be
determined in Phase 1. The tolerability and objective response rate at the RP2D will be evaluated in 
Phase 2.
4.1.1 PHASE 1
In the Phase I portion of the study, up to 5 pre-specified dose levels will be examined using the 
standard modified Fibonacci 3 + 3 design. ONC201 will be dosed orally once every 3 weeks (Arm

30 
Protocol 2014-0630
November 13, 2018
 
 
A) or once every 1 week (Arm B).
Subsequent to the February 9, 2016 amendment is IRB approved, enrollment in Arm A will cease.
Patients already enrolled in Arm A continue to receive ONC201 on the same dose regimen, as
stipulated by the protocol (see Section 6.6).
No intrapatient dose escalation or cross-over to Arm B is permitted. Dose escalation will continue
until an MTD is reached or dose level 5 is reached (625 mg), which will be declared the maximum
administered dose (MAD). The MAD or MTD, whichever is reached first in Arm B, will be defined
as the recommended Phase 2 dose (RP2D). It is anticipated that the eligible number of patients 
required for this Phase 1 part will be 36 patients.
A Phase I study has established 625mg ONC201 every one week as the recommended Phase II dose 
that is very well tolerated (see Section 1.15). Subsequent to IRB approval of the September 9, 2016 
amendment, enrollment in Phase I will cease and all new patients will be enrolled in Phase II. 
 
4.1.2 PHASE 2
Once the RP2D is determined, an expansion of 30 additional patients will be treated at the RP2D.
The primary endpoint is response rate, CR + PR. (For cutaneous T cell lymphomas, please refer to 
appendix 5 to 12 for disease classification and response assessments. Please also note that a separate 
correlative study (PA18-0191) will be conducted in parallel. PA18-0191 is approved by the MD 
Anderson IRB and will be co-submitted with protocol 2014-0630.)
 
 
 
4.2 TREATMENT SCHEDULE
 
All patients shall be registered with CORe (Clinical Oncology Research System) at (713) 745-2673 
prior to receiving therapy.
ONC201 will be administered in the clinic, i.e. as direct-observed therapy, for days when PK/PD 
samples are collected. Self-administration is permitted for days when the patient is not coming into the 
clinic for any other reason. 
All patients will be asked to record the medications they take at home and to bring the medication record 
they use to the clinic with them when they return to see their physician or research nurse. The patients 
will be provided with a specific medication form on which to record this information. Patients will also 
be asked to report any adverse events they experience during the course of the study. They will be given 
a form on which to record their information and this form will be returned on their next clinic visit to 
assist the research personnel in determining adverse events.
The dose of ONC201 will be assigned as described below. Following Cycle 1, therapy will continue in 
21-day cycles, until there is disease progression, unacceptable toxicity or the patient chooses to 

31 
Protocol 2014-0630
November 13, 2018
 
 
withdraw from therapy.  Growth factors and transfusions as needed are allowed after Cycle 1.
Overall response rate (ORR) (complete response + partial response [PR]) will be assessed by the 
Revised International Workshop Standardization Response Criteria for Non-Hodgkins Lymphoma 
(Appendix 2), with secondary assessment of the duration of response (DOR), progression free survival 
(PFS) and overall survival (OS). (For cutaneous T cell lymphomas, please refer to appendix 5 to 12 
for disease classification and response assessments.)
4.3 ONC201 STUDY DRUG ADMINISTRATION
ONC201 capsules are intended to be administered orally. The capsules should be swallowed intact
and subjects should not attempt to open capsules or dissolve them in water.
Patients should take designated capsules of ONC201 at approximately the same time of day for each 
administration and food should not be consumed either 2 hours prior or 2 hours post administration.  
ONC201 should be taken with a glass of water and consumed over as short a time as possible.
 
If a dose is missed, it can be taken up to 6 hours after the time it would have been taken. If it is later
than 6 hours, subjects should skip the dose.
 
If a dose is vomited and the subject can see all of the capsules taken, they can retake the dose. If a
dose is vomited and the subject cannot see all of the capsules, they should not retake the dose. The 
dose should be taken at the same time as usual the next day.
 
4.4 DOSE LEVELS TO BE STUDIED
ONC201 will be administered every 21 days in Arm A or every 7 days in Arm B. The same dose 
levels will be studied in Arm A and Arm B. The first cohort of subjects in each arm will receive
Dose Level 1.  
 
 
Dose Level
 
Dose of ONC201 (mg) 
Level 1
125
Level 2
250
Level 3
375
Level 4
500
Level 5
625
 
 
 
4.5 DOSE ESCALATION PROCESS
 
The first cohort of three subjects enrolled into the study will receive Dose Level 1. Following the
enrollment of the first patient in each cohort, the patient will be observed for 7 days prior to the 
second and third patient being enrolled into that cohort. A full safety evaluation will be conducted 

32 
Protocol 2014-0630
November 13, 2018
 
 
when these subjects have completed one cycle (21 days) of therapy. Prior to advancing/changing 
dose levels a cohort summary must be completed and submitted to the IND Medical Monitor for 
review and approval. All subjects enrolled into each cohort must complete one cycle of treatment 
prior to enrolling subjects into higher dose levels. Dose escalation for subsequent patients will 
proceed as follows:
 
 
•
If no Dose Limiting Toxicity (DLT) is reported in the first three subjects at a dose level, 
that dose level will be considered safe and three subjects will be enrolled at the next dose 
level. Toxicity information will continue to be evaluated from the time of the first protocol-
specific intervention, until 30 days from the last dose of study drug.
•
If 1/3 subjects in a cohort at a dose level has a DLT, the dose level will be expanded to 
obtain six evaluable subjects.
•
If 2/3 subjects in a cohort at a dose level has a DLT, that dose level will not be considered
safe, no further dose escalation will take place, and the MTD will have been exceeded*.
•
If there are < 2 subjects with a DLT among the expanded cohort of six evaluable subjects a
cohort of three subjects will be enrolled in the next higher dose level.
If there are 2 or more subjects with a DLT among the expanded cohort of six evaluable subjects,
that dose level will not be considered safe, no further dose escalation will take place, and the MTD
will have been exceeded*. The previous dose level at which < 1 of 6 patients experienced DLT will 
be declared the MTD. 
 
 
When the MTD has been exceeded: 
If less than 6 subjects have been treated in the next lower dose level (the possible MTD level),
additional subjects will be entered into this dose level until there are 6 subjects treated. If < 1 of 
these 6 subjects encountered DLT, then this dose level will be declared to be the MTD. If 2 or more
of the 6 subjects encounter DLT, then the MTD has been exceeded.
 
4.6 SUBJECT REPLACEMENT
Subjects, who discontinue study drug prior to the completion of their first 21-day study assessments 
for a reason other than an adverse event, will be replaced in order to have an adequate number of 
subjects for determination of the MTD.
4.7 DETERMINATION OF MAXIMUM TOLERATED DOSE
 
4.7.1 MAXIMUM TOLERATED DOSE
 
The maximum tolerated dose is defined as the highest dose that causes dose limiting toxicity in less
than one third of patients treated out of a 6 patient cohort, during the first cycle of treatment.
 
 
 
Patients Experiencing DLT
Required Action

33 
Protocol 2014-0630
November 13, 2018
 
0/3
Escalate to next dose level
1/3
Add 3 patients at current dose level
1/6
Escalate to next dose level
 
2/2, 2/3, 2/4, 2/5, 2/6
MTD exceeded – Confirm with previous dose level
with a total of 6 patients
NOTE: No more than 6 evaluable patients may be enrolled per dose level.
4.7.2 DOSE LIMITING TOXICITY
Dose limiting toxicity (DLT) will be assessed during the first course of each cohort (21 days), and 
refers to a study drug related or possibly related event which meets one of the following criteria
using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI
CTCAE) version 4.03:
•
Grade 3 or higher non-hematologic toxicity.
•
Grade 4 hematologic toxicity (ANC < 0.5 X 109/L and Platelet count < 25 X 109/L both
figures are considered DLT). [If bone marrow infiltration Platelet count < 15 X 109/L for the 
purposes of determining DLT)] Any grade 4 hematologic toxicity is a DLT, including
anemia.
•
Grade 3 neutropenia with elevated fever (defined as ANC < 1.0 X 109/L and > 101 degrees F
to be confirmed on two occasions).
Inability to receive the scheduled Day 1 dose of Cycle 2 within 14 days due to drug related
toxicity persisting from Cycle 1 or drug related toxicity newly encountered on Day 1 of
Cycle 2.
5
ONC201 STUDY DRUG SUPPLY
5.1 DESCRIPTION      
The study drug ONC201 is provided as 125 mg free base (approximately 150 mg of
dihydrochloride), without any excipients, filled into hydroxypropyl methylcellulose (HPMC) capsule
shells. ONC201 investigational drug product is intended for oral administration. Below is the chemical
name and structural depiction of ONC201•2HCl.
 
 
 
 
Chemical Name(s)
 
 
•
7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-
hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-
oney2HCl
 
 
 
 
 
Molecular Structure
 
 

34 
Protocol 2014-0630
November 13, 2018
 
 
 
 
Molecular Formula
C24H26N4O (free base)
 
C24H26N4O•2HCl (salt)
 
 
Molecular Weight
386.49 (free base)
459.41 (salt)
 
 
5.2 FORMULATION
Each capsule of drug product contains the equivalent 125mg of anhydrous ONC201 free base
with or without microcrystalline cellulose. This corresponds to ~150mg of drug substance
that corrects for the ONC201 dihydrochloride salt and moisture.
 
5.3 SHIPPING AND STORAGE
 
Study drug will be shipped to M.D. Anderson Cancer Center Investigational Pharmacy
before subjects are enrolled in the study.
 
The product is stored in a multi-dose container. The capsules are packaged in high-density
polyethylene (HDPE) white opaque bottles, closed with an induction seal and capped with a white
ribbed SecuRx® polypropylene (PPE) cap. The capsules are to be stored in the original closed
container at room temperature (15 to 30°C).
5.4 DRUG ACCOUNTABILITY
MD Anderson Cancer Center’s Investigational Pharmacy will maintain records of each shipment of 
investigational product. The records will document shipment dates, method of shipment, batch
numbers, and quantity of capsules contained in the shipment. Upon receipt of the investigational
product, the designated recipient at the study site will inspect the shipment, verify the number and
condition of the capsules, and prepare an inventory or drug accountability record.
 
Drug accountability records must be readily available for inspection by representatives of 
Oncoceutics, Inc. and by regulatory authorities.
 
Empty and partially used containers should be accounted for and destroyed at the study site in 
accordance with the internal standard operating procedures. Drug destruction records must be
readily available for inspection by representatives of Oncoceutics, Inc. and by regulatory authorities.
 
Only sites that cannot destroy unused drug on-site will be required to return their unused supply of
investigational product.
 
At the study site, all investigational study drugs will be stored in a locked, safe area to prevent 
unauthorized access. Investigators are prohibited from supplying ONC201 capsules to any subjects 
not properly enrolled in this study or to any physicians except those designated as sub-investigators
on Form FDA1572. The investigator must ensure that subjects receive ONC201 capsules only from 
personnel who fully understand the procedures for administering the drug.

35 
Protocol 2014-0630
November 13, 2018
 
 
If a drug shipment arrives damaged, or if there are any other drug complaints, a SAE/Product
Complaint Form or similar should be completed and sent via email to Oncoceutics Drug Safety or
designee by MD Anderson Cancer Center’s Investigational Pharmacy. Refer to the IB for additional
information regarding the drug product to be used in this trial.
6
DOSE MODIFICATIONS AND INITIATION OF A NEW CYCLE OF THERAPY
Subjects will be evaluated for AEs at each visit with the NCI Common Toxicity Criteria, Version
4.3
(see Appendix 4) used as a guide for the grading of severity. Refer to Section 6.1 for dose
reduction steps and Section 6.2 for instructions on dose modifications.
 
No dose modifications are permitted during Cycle 1 unless a DLT has been experienced. No dose 
escalations are permitted in any given patient once a dose level has been assigned. Patients
experiencing DLT during Cycle 1 may continue on therapy if the toxicity can be managed according
to the dose modification guidelines outlined below. However, the DLT event will contribute to the
assessment of MTD for that given cohort.
 
Dose modifications may be performed for all subsequent cycles. If the toxicities cannot be managed
by dose modification, the subject has to be withdrawn from the trial. Subjects who cannot tolerate 
ONC201 should be discontinued from the study (unless the subject has achieved a plateau phase of 
response to study therapy; such subjects will continue to adhere to the schedule of assessments
followed during the treatment phase of the study even though study drug has been discontinued).
Subjects who receive a dose of 80 mg and require a dose reduction should be discontinued from the 
study.
6.1 ONC201 DOSE REDUCTION STEPS
 
ONC201 Dose Reduction Steps
Starting Dose
Step –1
Step –2
125 mg
NA
NA
250 mg
125 mg
80 mg
375 mg
250 mg
125 mg
500 mg
375 mg
250 mg
625 mg
500 mg
375 mg
 
 
 
6.2 DOSE MODIFICATION GUIDELINES
 
Worst Toxicity
CTCAE Grade* unless otherwise specified (Value)
Dose Modification Guidelines
at any time DURING A CYCLE
of therapy
HEMATOLOGICAL TOXICITIES

36 
Protocol 2014-0630
November 13, 2018
 
 
Thrombocytopenia
Grade 4 (< 25 x 109/L) or 
Grade 3 or 4 with bleeding.
Temporarily discontinue ONC201. 
Repeat CBC weekly.
 
If not resolved to  grade 1 within 
the cycle, start new cycle with one 
level dose reduction of ONC201 
when the criteria for a new cycle are
met.
 
(Transfusion support is permitted
following cycle 1unless the patient 
experiences a DLT)
Neutropenia (ANC)
Grade 4 (ANC < 0.5 x
109/L) (This is considered a
DLT)
Temporarily discontinue ONC201 
Repeat CBC weekly.
 
If not resolved to  grade 1 within 
the cycle, start new cycle with one 
level
dose
reduction
of 
ONC201when the criteria for a new
cycle are met.
Febrile neutropenia
(ANC < 1.0 x 109/L, fever 
38.5°C)
Temporarily discontinue ONC201. 
Repeat CBC weekly.
 
If not resolved within the cycle,
start new cycle with one level dose 
reduction
of
ONC201 when the 
criteria for a new cycle are met.
NON-HEMATOLOGICAL TOXICITIES
 
Tumor Lysis 
Syndrome
(RI the following
increase in Cr, uric acid, or
Hold
ONC201
until
all
serum 
abnormalities have resolved.
Take
 
phosphate  increase in
K increase in 
calcium; or fold 
increase in LDH)
precautionary measures and resume
at full dose or one level reduction at
the investigators discretion.
Herpes Zoster
Any Grade
Hold ONC201 until lesions are dry.
Restart at full dose.

37 
Protocol 2014-0630
November 13, 2018
 
 
Peripheral 
Neuropathy
Grade 2 with pain or
grade 3
If persists for more than 2 week hold
ONC201 until resolved to grade 1
without pain. Restart at one level
dose reduction.
Grade 4
Discontinue ONC201
Congestive
Heart Failure
Any grade
Hold ONC201 until resolution or 
return to baseline. Continue at one 
level dose reduction. If not resolved
within 14 days discontinue ONC201
Infection
Grade 3 or 4
Hold
therapy
until
systemic 
treatment is complete. May resume
at same dose level.
Renal Insufficiency
Cr&OPL/min
Hold ONC201 until resolved and
resume at one level dose reduction.
Any other drug 
related toxicity
Grade 3
Hold drug until resolved to  Grade
1.
Resume
at
one
level
dose 
reduction
All dose modifications should be based on the worst preceding toxicity.
* Common Terminology Criteria for Adverse Events (CTCAE Version 4.03)
*** See also concomitant medication Section 6.4
 
 
6.3 INITIATION OF A NEW CYCLE OF THERAPY
A new course of treatment may begin on the scheduled Day 1 of a new cycle if:
•
The ANC is > 750/μL (growth factors allowed)
•
Platelet count > 50,000 (transfusions allowed)
•
(Patients who have bone marrow infiltration by MCL, DLBL, and/or TLCL are eligible if 
their ANC is  500/mm3 [growth factor allowed] or their platelet level is equal to or > than
30,000/mm3. These patients should be discussed with either the PI or Co-PI of the study
before treatment begins).
•
Hgb > 8 g/dL (red cell transfusions support is permitted)
•
Any other drug related adverse event that may have occurred has resolved to < Grade 1
severity.
 
If these conditions are not met on Day 1 of a new cycle, the subject will be evaluated weekly. A
new cycle will not be initiated until the toxicity has resolved as described above. In the event that a
new cycle cannot be initiated within 3 weeks of a scheduled Day 1, the patient must be removed
from study, unless in the opinion of the investigator the patient was benefitting from therapy. In this 
case, continuation of therapy must be approved by the Investigator.
 
6.4 CONCOMITANT THERAPY
All medications (prescription and non-prescription), treatments and therapies taken from the first day

38 
Protocol 2014-0630
November 13, 2018
 
 
of study drug through the end of the study, must be recorded on the source documents and PDMS.
Concomitant use of other anti-lymphoma therapy, including steroids, while the subject is on study
drug is prohibited. Corticosteroids for non-malignant conditions (e.g., asthma, inflammatory bowel
disease) equivalent to a dexamethasone dose  4 mg/day or prednisone  20 mg/day are not 
permitted.
 
The use of filgrastim (G-CSF) and erythropoietin for subjects in this study is permitted when used to 
treat neutropenia and anemia, respectively. Subjects should receive full supportive care, including
transfusions of blood and blood products, antibiotics, and antiemetics and prophylactic treatment for 
potential hypersensitivity reactions and tumor lysis syndrome when appropriate.
Avoid co-administration of acid-reducing agents as these agents may decrease the systemic exposure 
of ONC201. If acid-reducing agents cannot be avoided, use antacids instead of proton pump inhibitors 
or histamine-2 receptor antagonists.
6.4.1 REQUIRED PREGNANCY PREVENTION
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test prior
to initiation of therapy and must use acceptable methods of birth control during the study and for
90 days after the last dose of study drug. Men must agree to use a latex condom during sexual
contact with a female of childbearing potential during the study and for 90 days after the last dose of 
study drug even if they have has a successful vasectomy.
6.4.2 SAFETY CONSIDERATIONS
The safety profile of ONC201 in humans is unknown. Adverse reactions may occur following
treatment with ONC201. All subjects participating in trials of ONC201 should be closely monitored
for the occurrence of adverse events.
 
Because the potential for interaction of ONC201 with other concomitantly administered drugs through
the cytochrome P450 system is not known, the patient should avoid taking any agent known to affect
or with the potential to affect selected CYP450 isoenzymes.
Subjects with active or suspected infection of any kind that required systemic treatment should not 
be dosed with ONC201 until the infection has resolved and if being treated with anti-infective, the
course of antibiotics has been completed.
 
Hydroxyurea used to control peripheral blast counts is permitted within the first 2 cycles of treatment 
on study, but it must be stopped at least 24 hours before study drug administration in Cycle
3. Hydroxyurea also is permitted up to 24 hours before the first dose of study drug in patients with 
rapidly-proliferating disease.
6.5 TREATMENT COMPLIANCE
Treatment will be administered on an outpatient basis and each dose of administration will be
documented in the drug accountability records and source documentation.

39 
Protocol 2014-0630
November 13, 2018
 
 
6.6 DISCONTINUATION FROM TREATMENT
Treatment with study drug is to be discontinued when any of the following occur:
 
•
Disease Progression: Patients will be taken off-study if they have progressive disease (PD)
or clinically significant deterioration at any time during the study.
•
Personal Reasons: Patients may choose to withdraw from the study at any time.
•
Adverse Event(s) (AEs) that, in the judgment of the investigator, may cause severe or 
permanent harm or which rule out continuation of study drug.
•
Clinical Judgment of the Investigator: A patient may be withdrawn from the study, if in the 
opinion of the investigator, it is not in the patient's best interest to continue.
•
Requiring other anti-neoplastic therapies.
•
Major violation of the study protocol (i.e., unable to adhere to study schedule).
•
Lost to follow-up.
•
Death.
•
Confirmed or suspected pregnancy.
The date of discontinuation and reason(s) for patient discontinuation from the study will be recorded
in the chart and CORe. All evaluations which are required at the final study visit will be conducted
within 30 days of the last study drug treatment for each patient who discontinues treatment (with the
exception of patients that withdraw consent). Subjects will be followed for toxicity for 30 days
after the last dose of study drug(s).
 
7
VISIT SCHEDULE AND ASSESSMENT
7.1 STUDY PROCEDURES
The Investigator is responsible for keeping a record of all subjects who sign an Informed Consent 
Form and are screened for entry into the study. Screening assessments occur within 28 days from
first day of study drug administration (Cycle 1, Day 1). All laboratory assessments are to be done
with 14 days of first day of study drug administration, unless otherwise noted.
 
End of study evaluation should be scheduled within 30 days of the last study treatment or within
30 days of study discontinuation (with the exception of discontinuation due to patient withdraw of
consent). Follow-up contact with subjects should occur at a minimum of every 3 months via 
telephone from end of study date for a maximum of one year. An unscheduled visit can occur at any
time during the study. Source documentation must be maintained for these unscheduled visits. The
date for the visit and any data generated must be recorded in PDMS. PDMS/CORe will be used as
the electronic case report form for this study. Source documents for these unscheduled visits must also 
be maintained.
A schedule of the assessments can be found in Appendix 1, Schedule of Study Assessments.
 
 
7.1.1 SCREENING ASSESSMENTS
 
Screening visits may be scheduled within 28 days. See Appendix 1 for a list of required screening 
assessments. For cutaneous T cell lymphomas, please refer to Appendix 13.

40 
Protocol 2014-0630
November 13, 2018
 
 
7.1.2 ON-STUDY AND END OF STUDY ASSESSMENTS
Study visits and procedures may be scheduled with a +/- 3 day window except for Screening visit. 
See Appendix 1 for timing of all assessments. For cutaneous T cell lymphomas, please refer to 
Appendix 13.
 
7.1.3 EFFICACY ASSESSMENT
The endpoint for evaluating efficacy will be the objective response rate.
 
 
Response definitions for measurable disease from the Revised International Workshop Standardized
Response Criteria for non-Hodgkin's Lymphoma will be used (see Appendix 2). For cutaneous T cell 
lymphomas, please refer to Appendix 5 to 12 for disease classification and response assessments
 
7.1.4 SAFETY ASSESSMENTS
Safety assessments will consist of monitoring and recording all adverse events and serious adverse
events, the regular monitoring of hematology, blood chemistry values, vital signs, ECOG
performance status, and the regular physical examinations, ECG assessments and neurological
assessments.
 
Adverse events will be assessed according to the Common Toxicity Criteria for Adverse Events 
(CTCAE)
version
4.03.
CTCAE
v4.03
can
be
accessed
on
the
NIH/NCI
website
at:
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
 
7.1.5 PHARMACOKINETICS
For each patient, 3 tubes of > 5 mL of blood per tube will be collected into 2 EDTA tubes and 1 tube 
without anticoagulation. After the first dose of Cycle 1, the time points for blood draws will be at
baseline, at 30 minutes (± 15 minutes), 2 hours (± 30 minutes), 4 hours (± 30 minutes), 6 hours (±
30 minutes), 24 hours (± 1 hour), 48 hours (± 3 hours), 72 hours, 96 hours, and 168 hours (± 24
hours) ( following the first dose only). Thereafter, a pre-dose blood draw for PK will be taken on
day 1 of Cycles 2 and beyond and one additional blood draw will occur at the end of study visit.
For the second dose of ONC201, pre-dose blood samples will be drawn as a trough of the first dose.
All samples will be stored cryogenically until analysis.
 
7.1.6 ECG ASSESSMENTS
Single ECG assessments will be performed with standard 12-lead procedures. ECGs should be
performed at the time points indicated in the Study Calendar: baseline, Cycle 1 Day 1 (15 minutes ±
10 minutes, 1 hour ± 15 minutes, and 2 hours ± 30 minutes post-dose), Cycle 1 day 2, Cycle 1 Day
8, and when patients come off study. If indicated due to any cardiac abnormalities, two additional
ECGs must be performed at intervals approximately 3 minutes apart. Abnormalities in the ECG that

41 
Protocol 2014-0630
November 13, 2018
 
 
lead to a change in subject management (e.g., dose reduction of withheld, treatment discontinued,
requirement of additional medication or monitoring) or result in clinical signs and symptoms
considered clinically significant for the purposes of this study and will be deemed adverse events.
 
7.1.7 CORRELATIVE STUDIES
The mechanism of action of ONC201 appears to involve induction ER stress, TRAIL, and DR5, as
well as inactivation of Akt and ERK, at least in some tumor cells. Thus, the following markers will 
be assessed in tumor samples from consenting enrolled patients with measurable disease at baseline 
and post-treatment, as needed: DRD2, DRD5, TGM2, KSR-1, ATF4CHOP, DR5, Tunel, NK, 
CD4+ T cells, H&E, TRAIL, pERK, and pAkt. These markers will be assessed in circulating
lymphoma cells as available. We will look at plasma dopamine and prolactin levels at any time point 
where research-related plasma samples are drawn.
In aggregate, these tests would require at least 0.5mL plasma and 11 pretreatment tissue slides plus 7 
post-treatment slides.
 
TRAIL is localized to the cell surface, but is also cleaved to form a soluble truncated version that
remains bioactive. Thus TRAIL levels will be assessed in the serum of treated patients by ELISA
and in tumor cells by flow cytometry. Flow cytometry will also be utilized to investigate
intratumoral expression of CHOP, DR5, phospho–ERK, and phospho-Akt.
 
 
On cycle 1, PD samples will occur at baseline, 24 ± 12 hrs, 48 hours ± 12 hours, and 168 hours ± 24 
hours after administration of study drug on first cycle. A pre-dose PD sample will be taken on Day 1 
of Cycles 2 and beyond and one additional PD sampling will occur at the end of study visit.
 
Peripheral blood will be collected in 2 EDTA tubes and 1 blood collection tube without 
anticoagulant.
 
One EDTA tube will be dedicated to PK sampling of plasma that will be divided into 1mL aliquots
to avoid freeze-thaw cycles during analysis. The other EDTA tube will be used for PD to harvest 
circulating cells by centrifugal separation with Ficoll-Paque while the other tube, from which protein 
and RNA .
 
The PD tube without anticoagulant will be allowed to clot, and serum will be harvested by iterative
centrifugation for serum analysis (e.g., ELISA). All samples (protein, RNA, plasma, and serum) will
be stored cryogenically until analysis.
For cutaneous T cell lymphomas, please note that a separate correlative study (PA18-0191) will be 
conducted in parallel. PA18-0191 is approved by the MD Anderson IRB and will be co-submitted with 
protocol 2014-0630. Sample collections will mirror the time points for the CTCL arm as specified in 
Appendix 13. Briefly, at pre-dose Cycle 1 Day 1, and pre-dose Cycle 2 Day 1, blood will be drawn into 2 
mononuclear cell preparation tubes, 1 Streck tube, and 1 serum collection tube, for peripheral blood 

42 
Protocol 2014-0630
November 13, 2018
 
 
mononuclear cells (PBMC) separation, DNA/RNA extraction, and serum collection. The protein expression 
of ATF4, AKT, TRAIL, JAK/STAT, and NFNB molecules in T-cells will be evaluated by flow cytometry 
or/and western blot. Total RNA will be extracted from PBMCs and mRNA expression of aforementioned 
molecules will be evaluated by mRNA arrays. Flow cytometry will be performed at baseline and every 3 
cycles on patients with stage B2 or B1 at baseline  to assess CD4+, CD8+ and CD4+26- or CD7- T-cells in 
peripheral blood. Cytokines and soluble molecules in serum/plasma will be tested by cytokine array. In 
addition, at pre-dose Cycle 1 Day 1, and pre-dose Cycle 2 Day 1, 6mm punch biopsy will be collected to 
determine subsets of CD3, CD4, CD8 T-cells in epidermis and dermis, and protein expression including 
aforementioned biomarkers for ONC201 activity. The mRNA expression in skin lesions will also be 
evaluated by mRNA arrays and confirmed by immunohistochemistry
7.1.8 MD Anderson Symptom Inventory (MDASI)
The MD Anderson Symptom Inventory (MDASI) will be used to assess symptomatic status of the 
patients. The MDASI is a patient-reported outcome measure of the severity at its worst and 
interference with daily activities in the last 24 hours of common symptoms of cancer and its 
treatment.1 The MDASI has several advantages over other measures2,3: it is comprehensive yet brief 
enough to avoid being a burden to answer, it assesses both the severity of cancer-related symptoms 
and the level of symptom interference with functioning, its 0 to 10 numeric scale is readily understood 
by patients, and adaptable for telephone and electronic administration. The numeric rating scales are 
anchored on the ends with the descriptors 0=symptom not present or no interference and 10=the 
symptom is as bad as can be imagined or complete interference.1 Patients will complete the MDASI 
starting at screening and weekly until the start of therapy. The MDASI will then be completed weekly 
beginning on the day after the first dose of study drug for the first 3 cycles of therapy. Patients will 
then complete the MDASI the day after the start of each cycle of therapy and approximately 30 days 
(+/- 3 days) after discontinuation of study drug or before the start of subsequent treatment (whichever 
occurs first). In follow up, patients will complete the MDASI every 3 months for 1 year.  MDASI 
assessments may be completed on paper or electronic tablet when the patient is in clinic. When the 
patient is at home, the MDASI can be completed by Interactive Voice Response (IVR) automated 
telephone system, electronically through email, or by personal phone call with research staff. Patients
have the discretion to elect to forego completion of the MDASI at any time point. All data will be 
stored in the Department of Lymphoma/Myeloma. MDASI data collection quality and completeness 
will be monitored by Department of Lymphoma/Myeloma research staff.
 
7.1.9 FOLLOW-UP ASSESSMENTS
 
The date of discontinuation and reason(s) for patient discontinuation from the study will be recorded
in the chart. All evaluations which are required at the final study visit (and may be scheduled with a
+/-3 business day window) must be conducted for each patient who discontinues treatment. 
Subjects will be followed for toxicity for 30 days after the last dose of study drug(s).
 
 
Subjects will be followed via telephone every 3 months for information on progression of disease.
The exact date of death will be recorded.

43 
Protocol 2014-0630
November 13, 2018
 
 
For cutaneous T cell lymphomas, please refer to Appendix 13.
8
ADVERSE EVENTS
 
8.1 ADVERSE EVENTS DEFINITIONS
 
An adverse event (AE) is any untoward medical occurrence in a study subject administered an 
investigational product and that does not necessarily have a causal relationship with this treatment.
 
An AE therefore can be any unfavorable and unintended sign (including laboratory finding), symptom
or disease temporally associated with participation in an investigational study, whether or not
considered drug-related. In addition to new events, any increase in the severity or frequency of a pre-
existing condition that occurs after the subject signs a consent form for participation is considered
an AE. This includes any side effect, injury, toxicity, or sensitivity reaction.
 
An unexpected AE is any adverse drug event, the specificity or severity of which is not consistent 
with the current IB or prescribing information for a marketed compound. Also, reports which add
significant information on specificity or severity of a known, already documented AE constitute 
unexpected AEs. For example, an event more specific or more severe than described in the IB
would be considered “unexpected”.
 
Whenever possible, the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 
should be used to describe the event and for assessing the severity of AEs (see Appendix 4). Any
events representing a change in the CTCAE Grade need to be reported on the electronic AE case 
report form. This includes any change in laboratory values that the investigator feels are clinically
significant.
 
For AEs not adequately addressed in the CTCAE, the severity table below may be used:
 
Severity
Description
GRADE 1 – Mild
Transient or mild discomfort; no limitation in
activity; no medical intervention/therapy
required.
GRADE 2 – Moderate
Mild to moderate limitation in activity—some
assistance may be needed; no or minimal
medical intervention/therapy required.
GRADE 3 – Severe
Marked limitation in activity, some assistance
usually required; medical intervention/therapy
required, hospitalizations possible.
GRADE 4 – Life-
threatening
Extreme limitation in activity, significant
assistance required; life-threatening (immediate
risk of death); significant medical
intervention/therapy required, hospitalization or 
hospice care probable.
GRADE 5 – Fatal
Death
The investigator or attending physician must appraise all abnormal laboratory results for their clinical

44 
Protocol 2014-0630
November 13, 2018
 
 
significance, documenting with a signature if they are clinically significant or not. If any abnormal
laboratory result is considered clinically significant, the investigator or attending physician must
provide details about the action taken with respect to the test drug and about the patient's 
outcome.
 
Any condition, laboratory abnormality, or physical finding with an onset date prior to the subject
signing consent for study participation is considered to be pre-existing in nature and part of the 
subject’s medical history.
 
Adverse events and all protocol specific data will be entered into PDMS/CORe. PDMS/CORe will
be used as the electronic case report form for this protocol. For this protocol adverse events will be 
recorded in the medical record and entered into CORe.
 
The following are NOT considered AEs:
 
1. Pre-existing condition: A pre-existing condition (documented on the medical history CRF)
is not considered an AE unless the severity, frequency, or character of the event worsens 
during the study period.
2. Pre-planned or elective hospitalization: A hospitalization planned before signing the
informed consent form is not considered an SAE, but rather a therapeutic intervention. 
However, if during the pre-planned hospitalization an event occurs, which prolongs the 
hospitalization or meets any
other SAE criteria, the event will be considered an SAE.
Surgeries or interventions that were under consideration, but not performed before
enrollment in the study, will not be considered serious if they are performed after enrollment 
in the study for a condition that has not changed from its baseline level. Elective 
hospitalizations for social reasons, solely for the administration of chemotherapy, or due to 
long travel distances are also not SAEs.
3. Diagnostic Testing and Procedures: Testing and procedures should not to be reported as
AEs or SAEs, but rather the cause for the test or procedure should be reported.
4. Asymptomatic Treatment Related Lymphocytosis: This event should also not be 
considered an AE. Patients with treatment-related lymphocytosis should remain on study
treatment and continue with all study-related procedures.
8.2 ADVERSE EVENT CAUSALITY ASSESSMENT
 
The Investigator or physician designee is responsible for verifying and providing source
documentation for all adverse events and assigning the attribution for each event for all subjects 
enrolled on the trial
 
Adverse events will be documented in the medical record and entered into CORe (the electronic case
report form for this protocol).
 
Using the following criteria, the relationship of the AE to the study drug should be assessed as 
follows:
 

45 
Protocol 2014-0630
November 13, 2018
 
 
Yes:  The event is suspected to be related if:
•
there is a clinically plausible time sequence between onset of the AE and administration of 
study treatment; and/or
•
there is a biologically plausible mechanism for the study treatment to cause or contribute to 
the AE; and/or
•
the event responds to withdrawal of the study medication (dechallenge) and/or recurs with 
rechallenge (when clinically feasible); and/or
•
the AE cannot be reasonably attributed to concurrent/underlying illness, other drugs, or 
procedures
 
No: The event is NOT suspected to be related if:
 
•
the AE is more likely to be explained by the subject’s clinical state, underlying disease, 
concomitant medication, study or non-study procedure; and/or
•
the time of occurrence of the AE is not reasonably related to administration of study
treatment; and/or
•
the event is unlikely to be related to the investigational product(s)
The relationship assessment of the adverse event by the investigator should be documented as
follows:
 
•
Unrelated: The AE is clearly NOT related to the treatment.
•
Unlikely Related: The AE is doubtfully related to the treatment.
•
Possibly Related: The AE may be related to the treatment.
•
Probably Related: The AE is likely related to the treatment
•
Definitely Related: The AE is clearly related to the treatment.
8.3 SERIOUS ADVERSE EVENT REPORTING (SAE) FOR MD ANDERSON-SPONSORED
IND PROTOCOLS
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either
the investigator or the sponsor, it results in any of the following outcomes:
 

Death

A life-threatening adverse drug experience – any adverse experience that places the patient, 
in the view of the initial reporter, at immediate risk of death from the adverse experience as it 
occurred. It does not include an adverse experience that, had it occurred in a more severe form, 
might have caused death.

Inpatient hospitalization or prolongation of existing hospitalization
 

A persistent or significant incapacity or substantial disruption of the ability to conduct
normal life functions.
 

A congenital anomaly/birth defect.
 
Important medical events that may not result in death, be life-threatening, or require hospitalization 
may be considered a serious adverse drug experience when, based upon appropriate medical
judgment, they may jeopardize the patient or subject and may require medical or surgical

46 
Protocol 2014-0630
November 13, 2018
 
 
intervention to prevent one of the outcomes listed in this definition. Examples of such medical 
events include allergic bronchospasm requiring intensive treatment in an emergency room or at
home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse (21 CFR 312.32).
 
Important medical events as defined above may also be considered serious adverse events. Any
important medical event can and should be reported as an SAE if deemed appropriate by the
Investigator or the IND Sponsor, MDACC IND Office.
 
All events occurring during the conduct of a protocol and meeting the definition of a SAE must be
reported to the IRB in accordance with the timeframes and procedures outlined in “The University of
Texas M. D. Anderson Cancer Center Institutional Review Board Policy for Investigators on 
Reporting Unanticipated Adverse Events for Drugs and Devices”. Unless stated otherwise in the 
protocol, all SAEs, expected or unexpected, must be reported to the IND Office, regardless of
attribution (within 5 working days of knowledge of the event).
 
All life-threatening or fatal events, that are unexpected, and related to the study drug, must have a
written report submitted within 24 hours (next working day) of knowledge of the event to the Safety
Project Manager in the IND Office.
 
Unless otherwise noted, the electronic SAE application (eSAE) will be utilized for safety reporting
to the IND Office and MDACC IRB. Serious adverse events will be captured from the time of the
first protocol-specific intervention, until 30 days after the last dose of drug, unless the participant
withdraws consent. Serious adverse events must be followed until clinical recovery is complete and
laboratory tests have returned to baseline, progression of the event has stabilized, or there has been
acceptable resolution of the event.
 
Additionally, any serious adverse events that occur after the 30 day time period that are related to the
study treatment must be reported to the IND Office. This may include the development of a
secondary malignancy.
8.3.1 OTHER MALIGNANCIES
In addition to all routine adverse event reporting, all other malignant tumors including solid tumors, 
skin malignancies and hematologic malignancies are to be reported for the duration of study treatment
and during any protocol-specified follow-up periods including post-progression follow-up for overall 
survival.
8.4 INVESTIGATOR REPORTING RESPONSIBILITIES
The conduct of the study will comply with all FDA safety reporting requirements. The Investigator
has the obligation to report all serious adverse events to the MDACC IRB via the Office of Protocol 
Research to Oncoceutics and to the IND office. This study will be monitored for compliance by the 
IND office.
8.4.1 INVESTIGATOR COMMUNICATIONS WITH ONCOCEUTICS
 

47 
Protocol 2014-0630
November 13, 2018
 
 
The investigator should inform Oncoceutics of any SAE.
 
This must be documented on an MD Anderson SAE Form and will be reporting as per Section 8.3. 
The initial report must be as complete as possible, including details of the current illness and
(serious) adverse event, and an assessment of the causal relationship between the event and the
investigational product(s). Information not available at the time of the initial report (e.g., an end date
for the adverse event or laboratory values received after the report) must be documented on a follow-
up MD Anderson SAE Form.
 
The Investigator must inform Oncoceutics via fax at the contact information listed below.
Notification should include MD Anderson SAE Form and a cover page. Non-expedited SAEs must 
be reported to Oncoceutics on a regular basis within 30 days of occurrence in the form of an SAE
report.
8.4.1.1 Oncoceutics Drug Safety and Pharmacovigilance
Oncoceutics Contact Information:
Phone: 1-844-ONCORXS (1-844-662-6797); Extension 100
e-mail: pharmacovigilance@oncoceutics.com
 
8.4.1.2 PREGNANCY REPORTING TO ONCOCEUTICS
Female patients of childbearing potential must have a negative serum or urine pregnancy test within 
7 days prior to the administration of the first dose of study treatment and agree to use an effective 
method of contraception during the study and for 90 days following the last dose of study treatment. 
Contraception must be in place at the latest 2 weeks prior to initiating study treatment and be 
continued during study drug dose interruption intervals. If a menstrual period in a treated woman
does not occur at the anticipated timing a pregnancy test should be performed.
 
A female of childbearing potential is a sexually mature woman who: 1) has not undergone a
hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24
consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
 
Male patients must use an effective barrier method of contraception during the study and for 90 days 
following the last dose of study treatment if sexually active with a female of childbearing potential.
 
Pregnancies occurring while a female subject is on ONC201 or within 4 weeks after the subject's last 
dose of ONC201 or within 3 months of the last dose for a pregnancy in a female partner of a male 
subject, are considered reportable occurrences. Subjects, spouses, or partners will be followed
through the outcome of the pregnancy. If the subject is on ONC201, it is to be discontinued
immediately. The pregnancy must be reported by the investigator to the MDACC IRB and IND
Offices, to Oncoceutics as per the SAE timelines listed in Sections 8.3 and 8.4.1.
 
The Investigator will follow the subject until completion of the pregnancy, and must notify
Oncoceutics of the outcome as specified below as per the SAE timelines listed in Sections 8.3 and
8.4.1.
 

48 
Protocol 2014-0630
November 13, 2018
 
 
If the outcome of the pregnancy meets the criteria for immediate classification as an SAE (i.e., 
spontaneous abortion [any congenital anomaly detected in an aborted fetus is to be documented],
stillbirth, neonatal death, or congenital anomaly), the Investigator should follow the procedures for
reporting SAEs (i.e., report the event to Oncoceutics and report the event to the MDACC IRB and
IND Offices.
 
All neonatal deaths that occur within 30 days of birth should be reported, without regard to causality,
as SAEs. In addition, any infant death after 30 days that the Investigator suspects is related to the in
utero exposure to ONC201 should also be reported.
 
In the case of a live "normal" birth, Oncoceutics, the MDACC IRB and IND Offices should be 
advised as soon as the information is available.
 
8.5 ADVERSE EVENT UPDATES AND IND SAFETY REPORTS
Oncoceutics will notify the Investigator via an IND Safety Report of the following information:
Any AE associated with the use of study drug in this study or in other studies that is both serious and
unexpected, any changes on the investigational brochure or any other safety information that changes
the risk/benefit profile of ONC201, respectively, during the conduct of the study.
 
Any finding from tests in laboratory animals that suggests a significant risk for human subjects; 
including reports of mutagenicity, teratogenicity, or carcinogenicity.
 
The Investigator shall notify his/her IRB promptly of these new serious and unexpected AE(s) or 
significant risks to subjects.
 
The Investigator must keep copies of all AE information, including correspondence with 
Oncoceutics and the IRB, on file.
 
9
STATISTICS ANALYSIS
 
9.1 STUDY DESIGN
This will be a single-center, Phase 1/2 clinical trial in patients with refractory or relapsed B cell 
lymphoma. The feasibility of administrating ONC 201 and the recommended Phase 2 dose (RP2D)
will be determined in Phase 1. The tolerability and objective response rate at the RP2D will be
evaluated in Phase 2.
9.1.1 PHASE 1
The primary objectives of Phase 1 (dose escalation) are to assess the feasibility, safety and tolerability
of ONC 201 and to determine the recommended Phase 2 dose (RP2D) of ONC201. Dose escalation
will be guided by standard 3+3 design. ONC201 will be dosed orally once every 3 weeks (Arm A)
or 1 week (Arm B). Once the February 9, 2016 amendment is IRB approved, enrollment in Arm A
will cease. Patients already enrolled in Arm A will continue to receive ONC201 on the same dose
regimen, as stipulated by the protocol (see Section 6.6). No intrapatient dose escalation or cross-
over to Arm B is permitted. For each arm, the first cohort of 3 patients will be treated at Dose

49 
Protocol 2014-0630
November 13, 2018
 
 
Level 1 and evaluated for DLT (defined in section 4.7.2) at the end of first cycle (21 days). The
algorithm is as follows: (1) If 0 out of 3 patients experiences dose-limiting toxicity (DLT), the next
cohort of 3 patients will be treated at the next higher dose level. (2) If 1 out of 3 patients develop
a DLT, an additional 3 patients will be treated at the same dose level. If no more DLTs develop 
at this dose (i.e., 1 out of a total of 6 patients develops a DLT), the dose escalation continues for the
next cohort of 3 patients. (3) At any given dose, if greater than 1 out of 3 patients or 1 out of 6 patients
experience DLT, the dose level exceeds the MTD and 3 more patients will be treated at the next
lower dose if there are less than 6 patients already treated at that dose. Following the above scheme,
MTD is defined as the highest dose level in which 6 patients have been treated with less than 2
instances of DLT. Given 5 predefined dose levels (given in section 4.4), it is anticipated that the
eligible number of patients required for the Phase I part will be up to 30 patients. The MAD or 
MTD, whichever is reached first in Arm B, will be defined as the RP2D.
9.1.2 PHASE 2
 
Once the RP2D is determined, an expansion of 30 additional patients will be treated at the RP2D.
The primary objective is to confirm the safety and tolerability at the RP2D and to assess tumor
response in subjects with advanced lymphoma. The primary endpoint is overall response (OR)
defined as either complete response (CR) or partial response (PR) observed in the first 3 treatment
cycles. A Bayesian method by Thall et al (1995) will be used for futility and toxicity monitoring. The
trial will be stopped early if
Pr (OR rate < 0.10 |data) > 0.90
or
 
Pr (DLT rate > 0.30 | data) > 0.90
 
That is, the trial will be stopped early if there is more than a 90% probability that the OR rate is lower 
than 10% or if there is more than a 90% probability that the DLT rate is higher than 30%. We assume 
that OR and DLT follow a prior distribution of beta (0.1, 0.9) and beta (0.3, 0.7), respectively. DLTs 
for phase II toxicity monitoring are the same as those defined in section 4.7.2 for the phase I trial.
The above futility and toxicity monitoring rules will be implemented starting from the 12th patient
in Phase 2. The corresponding stopping boundaries are listed in the following Table 9.1 and Table
9.2. If the number of responses required for moving the trial to next stage has not been achieved, the
patient enrollment will be halted until enough responses observed. For example, if there is no OR in
the first 12 patients, stop the trial early due to futility. The trial also needs to be stopped early due
to the agent is too toxic if there are 6 or more patients experience DLTs among the first 12 patients.
 
For cutaneous T cell lymphomas, please note that a separate correlative study (PA18-0191) will be 
conducted in parallel. PA18-0191 is approved by the MD Anderson IRB and will be co-submitted 
with protocol 2014-0630.)
 
 
 
Table 9.1: The stopping boundaries of Phase II trial

50 
Protocol 2014-0630
November 13, 2018
 
 
 
Number of patients evaluated
Recommend stopping if 
Overall Response observed
Recommend stopping if
ıToxicity observed
12
0
6-12
18
0
9-18
24
0-1
11-24
30
Always stop with this many patients
 
Table 9.2: The operating characteristics are summarized in the following table (based on 
simulations from 10,000 trials).
 
True OR Rate
True Toxicity
Rate
Prob(stop the trial
early)
Average number of
patients treated
0.05
0.10
0.725
19.2
 
0.30
0.767
18.2
 
0.50
0.944
14.3
0.10
0.10
0.389
24.3
 
0.30
0.483
22.6
 
0.50
0.876
15.7
0.20
0.10
0.083
28.7
 
0.30
0.223
26.4
 
0.50
0.813
17.0
 
The above stopping boundaries and operating characteristics are calculated using MultcLean 
(v.2.1.0) design software downloaded from http://biostatistics.mdanderson.org/SoftwareDownload.
 
External Data Safety Monitoring Board (eDSMB) toxicity and efficacy monitoring
 
 
1. Phase I
a.
Toxicity data summary of adverse events and Serious Adverse Events (SAE) with 
grade and relationship per cohort, treatment related deaths, and will be reviewed by
the eDSMB.
b. The eDSMB review of Phase I toxicity data will be done:
i. Annually (from the date of first administration of ONC201 to a
study participant); and
ii. Upon completion of Phase I of the study prior to initiation of Phase II of
the study.
2. Phase II
a.
Efficacy data Summary as per protocol objectives will be reviewed by the eDSMB.
b. Toxicity data summary of adverse events and Serious Adverse Events (SAE) with 
grade and relationship per cohort, treatment related deaths, and will be reviewed by
the eDSMB.
c.
The eDSMB review of Phase II toxicity and efficacy data will be done as follows:
i. Once the Phase II portion of the study has been opened, only 1 patient can be 
added. Upon enrollment of this patient, the PI should request that the study be 
closed to new patient entry until approval regarding safety is given from the 

51 
Protocol 2014-0630
November 13, 2018
 
 
eDSMB. This one patient must be fully evaluated for DLT before any 
additional patients can be added. Update the committee on any toxicity issues 
that may have occurred with this patient.;
ii. If the Committee has deemed the new dosage as safe, the CNPE status can be 
lifted and 2 additional patients can be added. The PI should report an update to 
the eDSMB regarding toxicity for all 3 patients. Again, the protocol should be 
CNPE during this time period by the PI;
iii. If the eDSMB finds that there has been no change regarding safety, 3 more 
patients can be enrolled. Again, the study would be CNPE after the enrollment 
of these 3 patients for eDSMB review of safety for all 6 patients. If there has 
been no change in safety, the study will re-open to accrual and will be reviewed 
at this protocol’s annual eDSMB review in November 2017.
The investigator is responsible for completing the response/toxicity summary report and submitting it 
to the IND office Medical Monitor for review.  This should be submitted after the first 12 evaluable 
patients complete 3 treatment cycles and every 6 evaluable patients, thereafter.  On every report 
submission, the information from previously reported patients will need to be updated.
9.1.3 ANALYSIS PLAN
 
Data analysis will be performed using SAS or R, as appropriate. If RP2D is equal to MTD, statistical
analysis on MTD will be conducted on the combined data including both the 6 patients treated at
MTD in Phase 1 and up to 30 patients in Phase 2. The OR rate and the DLT rate will be summarized
by frequency and 95% confidence interval. Patients who received at least one dose of the treatment 
drug will be evaluable for toxicity outcomes. Toxicities will be summarized by dose levels, by grade
and by their relationship to the treatment. The intent-to-treat patients will be used for the primary
efficacy analysis, patients who lost-to-follow up in the first 3 cycles will be treated as failures. The 
distribution of time-to-event endpoints including OS and PFS will be estimated by the method of 
Kaplan and Meier Analysis.  Comparison of time-to-event endpoints by important subgroups will be 
made using the log-rank test.  Cox proportional hazard regression will be employed for multivariate 
analysis on time-to-event outcomes.
 
 
10. RESPONSE CRITERIA
 
 
Response definitions for measurable disease from the Revised International Workshop Standardized
Response Criteria for non-Hodgkin's Lymphoma will be used (see Appendix 2). Patients will be
assessed for response after every 3 cycles of therapy. Patients with stable disease (SD) or better may
continue on therapy until disease progression.
For cutaneous T cell lymphomas, please refer to Appendix 5 to 12 for disease classification and 
response assessments.

52 
Protocol 2014-0630
November 13, 2018
 
 
 
10.1 COMPLETE RESPONSE (CR)
 
1.
Complete disappearance of all detectable clinical evidence of disease and disease-related 
symptoms if present before therapy.
 
2a. Typically FDG-avid lymphoma: in patients with no pretreatment PET scan or when the PET
scan was positive before therapy, a post-treatment residual mass of any size is permitted as
long as it is PET negative.
 
2b.
Variably FDG-avid lymphomas/FDG avidity unknown: in patients without a pretreatment PET
scan, or if a pretreatment PET scan was negative, all lymph nodes and nodal masses must have 
regressed on CT to normal size ( 1.5 cm in their greatest transverse diameter for nodes > 1.5
cm before therapy). Previously involved nodes that were 1.1 to 1.5 cm in their long axis and
more than 1.0 cm in their short axis before treatment must have decreased to 1.0 cm in their 
short axis after treatment.
 
3.
The spleen and/or liver, if considered enlarged before therapy on the basis of a physical
examination or CT scan, should not be palpable on physical examination and should be 
considered normal size by imaging studies, and nodules related to lymphoma should disappear.
However, determination of splenic involvement is not always reliable because a spleen 
considered normal in size may still contain lymphoma, whereas an enlarged spleen may reflect 
variations in anatomy, blood volume, the use of hematopoietic growth factors, or causes other
than lymphoma.
 
4.
If the bone marrow was involved by lymphoma before treatment, the infiltrate must have
cleared on repeat bone marrow biopsy.
The biopsy sample on which this determination is 
made must be adequate (with a goal of > 20 mm unilateral core).
If the
sample is
indeterminate by morphology, it should be negative by immunohistochemistry. A sample that 
is negative by immunohistochemistry but that demonstrates a small population of clonal
lymphocytes by flow cytometry will be considered a CR until data become available 
demonstrating a clear difference in patient outcome.
 

Protocol 2014-0630
November 13, 2018
 
 
53
10.2 PARTIAL RESPONSE (PR)
 
1.
At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest 
dominant nodes or nodal masses. These nodes or masses should be selected according to all of 
the following: they should be clearly measurable in at least 2 perpendicular dimensions; if 
possible they should be from disparate regions of the body; and they should include 
mediastinal and retroperitoneal areas of disease whenever these sites are involved.
2.
No increase should be observed in the size of other nodes, liver, or spleen.
3.
Splenic and hepatic nodules must regress by  50% in their SPD or, for single nodules, in the 
greatest transverse diameter.
4.
With the exception of splenic and hepatic nodules, involvement of other organs is usually
assessable and no measurable disease should be present.
5.
Bone marrow assessment is irrelevant for determination of a PR if the sample was positive 
before treatment. However, if positive, the cell type should be specified (e.g., large-cell
lymphoma or small neoplastic B cells). Patients who achieve a CR by the above criteria, but 
who have persistent morphologic bone marrow involvement will be considered partial
responders.
When the bone marrow was involved before therapy and a clinical CR was achieved, but
with no bone marrow assessment after treatment, patients should be considered partial
responders.
6.
No new sites of disease should be observed.
7.
Typically FDG-avid lymphoma: for patients with no pretreatment PET scan or if the PET scan
was positive before therapy, the post-treatment PET should be positive in at least one
previously involved site.
8.
Variably FDG-avid lymphomas/FDG-avidity unknown:  for patients  without  a pretreatment 
PET scan, or if a pretreatment PET scan was negative, CT criteria should be used.
 
In patients with follicular lymphoma or mantle-cell lymphoma, a PET scan is only indicated with
one or at most two residual masses that have regressed by more than 50% on CT; those with more
than two residual lesions are unlikely to be PET negative and should be considered partial
responders.
10.3 STABLE DISEASE (SD)
A patient is considered to have SD when he or she fails to attain the criteria needed for a CR or PR,
but does not fulfill those for progressive disease (see Relapsed Disease [after CR]/Progressive
Disease [after PR, SD]).
 
1.
Typically FGD-avid lymphomas: the PET should be positive at prior sites of disease with
no new areas of involvement on the post-treatment CT or PET.
 

Protocol 2014-0630
November 13, 2018
 
 
54
2.
Variably FDG-avid lymphomas/FDG-avidity unknown: for patients without a pretreatment 
PET scan or if the pretreatment PET was negative, there must be no change in the size of the 
previous lesions on the post-treatment CT scan.
 
10.4 RELAPSED DISEASE (AFTER CR) /PROGRESSIVE DISEASE (AFTER PR, SD)
Lymph nodes should be considered abnormal if the long axis is more than 1.5 cm regardless of the
short axis. If a lymph node has a long axis of 1.1 to 1.5 cm, it should only be considered abnormal
if its short axis is more than 1.0. Lymph nodes  1.0 x  1.0 cm will not be considered as abnormal
for relapse or progressive disease.
 
1.
Appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy,
even if other lesions are decreasing in size. Increased FDG uptake in a previously unaffected 
site should only be considered relapsed or progressive disease after confirmation with other
modalities. In patients with no prior history of pulmonary lymphoma, new lung nodules
identified by CT are mostly benign. Thus, a therapeutic decision should not be made solely on 
the basis of the PET without histologic confirmation.
2.
At least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single 
involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered
progressive disease, a lymph node with a diameter of the short axis of less than 1.0 cm must 
increase by  and to a size of 1.5 x 1.5 cm or more than 1.5 cm in the long axis.
3.
At least a 50% increase in the longest diameter of any single previously identified node more
than 1 cm in its short axis.
4.
Lesions should be PET positive if observed in a typical FDG-avid lymphoma or the lesion was
PET positive before therapy unless the lesion is too small to be detected with current PET
systems (< 1.5 cm in its long axis by CT).
 
Measurable extra nodal disease should be assessed in a manner similar to that for nodal disease. For 
these recommendations, the spleen is considered nodal disease. Disease that is only assessable (e.g.,
pleural effusions, bone lesions) will be recorded as present or absent only, unless, while an
abnormality is still noted by imaging studies or physical examination, it is found to be histological
negative.
 
In clinical trials where PET is unavailable to the vast majority of participants, or where PET is not 
deemed necessary or appropriate for use (e.g., a trial in patients with MALT lymphoma), response 
should be assessed as above, but only using CT scans. However, residual masses should not be 
assigned CR/unconfirmed (Cru) status, but should be considered partial responses.

Protocol 2014-0630
November 13, 2018
 
 
55
APPENDICES
 
 
APPENDIX 1
Table of Assessments
 
Study visits and procedures
may be scheduled with a +/-
3
business
day
window
Screening
Cycle 1 (D1 – 21)
Cycle 2 +
End of Treatment
Follow-
up
 
Within 28
days*
Day 1
Day 2
Day 8
Day 9
Day 15
Day 16
Day 1
Day 2
30 ( +/- 3) days
post last dose)17
 
Medical/RX history1
X
 
 
 
 
 
 
 
 
 
 
Physical exam, ECOG, Height,
X
X
 
(X)2
(X)2
X2
X
 
Vital signs3
X
X
 
X
X
 
 
X
 
Neurologic assessment4
X
X
 
 
 
 
X14
X
 
12-lead ECG14
X
X14
X14
X14
 
 
 
 
X
 
Hematology5
X
X
 
X
X
X
X
 
Full serum chemistries6
X
X
 
X
X
X
X
 
Coagulation tests7
X
 
 
 
 
 
 
 
X
 
Pregnancy test8
X8
 
 
 
 
 
X
X
 
CT chest/abd/pelvis/neck (if
applicable)
X
 
 
 
 
 
X9, 10
X10
 
CXR
X
 
 
 
 
 
 
 
X
 
Unilateral BMB and aspirate
X11
 
 
 
 
 
X11
X
1
 
Colonoscopy/GI endoscopy
X12
 
 
 
 
 
X12
X
1
 
Other imaging/PET
X
 
 
 
 
 
X9, 10
X
 
ONC 201 administration13
 
X
 
 
 
 
X
 
 
 
Blood sample for PK
 
X15
 
 
 
 
X19
X
 
Blood/tissue samples for
Correlative studies
X19            
(tissue only)
(optional) 
X10,16
 
 
 
 
X10,20
X10
 
Adverse events
 
 
 
 
 
 
Concomitant medications
 
 
 
 
 
 
Disease status and survival
 
 
 
 
 
 
 
 
 
 
X18
MDASI21
X
X
X
X
X21
X
X21

Protocol 2014-0630
November 13, 2018
 
 
56
 
Footnotes Table of Assessments 
(X) Parentheses indicate that the particular test is situational at that time point, as specified in the respective footnote.
*
All laboratory assessments are to be done with 14 days of first day of study drug administration, unless otherwise noted.
1.
Medical history: prior treatments for lymphoma, significant medical conditions, neuropathy history.
2.
Physical examination: review of systems, height at baseline, weight, and if significant weight loss or gain (+/- 10%). Abbreviated PE on Days 8 and 15 of Cycle 1 and Days 
1 of each cycle or as clinically indicated.
3.
Vital signs: systolic and diastolic blood pressure, respiration, pulse, oral temperature prior to dosing.
4.
Neurologic exam: evaluate peripheral neuropathy and/or changes in preexisting neuropathy.
5.
Hematology: hemoglobin, hematocrit, WBC with complete manual differential (neutrophils [segmented and bands], lymphocytes, monocytes, eosinophils, basophils), 
RBCs, platelet count (For Day 1, screening panel may be used if within 24 hours prior to initiation of therapy). Obtain and review on Day 1 of all cycles prior to each dose
of ONC 201, on Days 8 and 15 of Cycle 1, and as clinically indicated.
6.
Full blood chemistry panel: BUN, creatinine, glucose, uric acid, bicarbonate, calcium, chloride, phosphorus, potassium, sodium, albumin, total protein, magnesium, total
bilirubin, alkaline phosphatase, ALT, AST, LDH (for Day 1 screening panel may be used if within 24 hours prior to starting treatment). Obtain and review prior to each 
dose of ONC201 on Day 1 of each subsequent cycle, on Days 8 and 15 of Cycle 1, and as clinically indicated. Serum ȕ2 microglobulin, viral hepatitis panel including
HBsAg, HBcore antibody, HB antibody, Hep C antibody, and GGT at baseline.
7.
Coagulation tests: prothrombin time, activated partial thromboplastin time, and international normalized ratio (historical panel may be used if within 14 days prior to starting
treatment) 1st day of study drug
8.
Pregnancy Test –urine or serum in women of child bearing potential. If a menstrual period in a treated woman does not occur at the anticipated timing a pregnancy test
should be performed. A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not
been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
9.
Disease Assessment every other cycle beginning on cycle 3 (i.e. every odd cycle): Obtain bi-dimensional measurements when measurable disease is present unless it 
becomes PET negative (see response assessment criteria in Appendix 2). Either a PET/CT or a CT can be used before and/or after treatment to assess response.
10. Repeat every other cycle beginning on cycle 3 (i.e. every odd cycle) for the duration of treatment. Perform only those evaluations with known or suspected sites of disease.
If no change in persistent mass, a biopsy is to be performed, if feasible.
11. Send baseline bone marrow aspirate for cytogenetics and lymphoma markers. FISH for IgH/cyclin D1 may be required to make a definitive diagnosis if bone marrow is
inconclusive. Repeat only if initially positive and send bone marrow aspirate for lymphoma markers. Repeat bone marrow biopsy to confirm CR.
12. Baseline colonoscopy and other GI endoscopies are required only if this is the main area of disease response assessment.  If in CR by radiologic evaluation, bone marrow or 
blood test at any time, do colonoscopy with random biopsy and bone marrow biopsy and PET scan if necessary and possible to confirm CR.
13. ONC201 administration: See Section 4 for study drug administration and Section 6.2 for dose modification guidelines.
14. ECG: baseline, Cycle 1 Day 1 (15 minutes ± 10 minutes, 1 hour ± 15 minutes, and 2 hours ± 30 minutes post-dose), Cycle 1 day 2, Cycle 1 Day 8, and when patients come
off study. If indicated due to any cardiac abnormalities, two additional ECGs must be performed at intervals approximately 3 minutes apart.
15. Blood draws taken at baseline, 30 ± 15 minutes, 2 hours ± 30 minutes, 4 hours ± 30 minutes, 6 hours ± 30 minutes, 24 ± 1 hour , 48 hours ± 12 hours, 72 ±  12 hours, 96 
±  12 hours, and 168 hours ± 24 hours following administration in the first cycle.
16. Blood draws taken at baseline, 24 ± 1 hour, 48 hours ± 12 hours, and 168 hours ± 24 hours following administration in the first cycle. PD samples can be collected in
parallel to PK samples. Each PD blood draw will include one EDTA tube and one tube without anticoagulant.
17. Approximately 30 days (+/- 3) after discontinuation of all study drugs or before start of subsequent treatment (whichever occurs first).
18. Every 3 months via telephone for all subjects for 1 year.

Protocol 2014-0630
November 13, 2018
 
 
57
19. For patients with measurable disease, optional core tumor biopsy will be collected at Screening for correlative studies. If patient has had a core biopsy within 12 months, a
formalin-fixed paraffin embedded tumor block or slides may be used instead. See Section 7.1.7 for correlative studies to be run.   
20. Blood draws taken pre-dose for Cycle 2 and beyond. PD samples can be collected in parallel to PK samples. Tissue samples will be taken at re-staging, as clinically indicated 
(See footnote 10.)
21. Patients will complete the MDASI starting at screening and weekly until the start of therapy. The MDASI will then be completed weekly beginning on the day after the first 
dose of study drug for the first 3 cycles of therapy (C1D2, C1D9, C1D16, C2D2, C2D9, C2D16, C3D2, C3D9, C3D16). Patients will then complete the MDASI the day after 
the start of each cycle of therapy (C4+D2) and approximately 30 days (+/- 3 days) after discontinuation of study drug or before the start of subsequent treatment (whichever 
occurs first). In follow up, patients will complete the MDASI every 3 months for 1 year. MDASI assessments may be completed on paper or electronic tablet when the patient 
is in clinic. When the patient is at home, the MDASI can be completed by Interactive Voice Response (IVR) automated telephone system, electronically through email, or by 
personal phone call with research staff. Patients have the discretion to elect to forego completion of the MDASI at any time point. All data will be stored in the Department of 
Lymphoma/Myeloma. MDASI data collection quality and completeness will be monitored by Department of Lymphoma/Myeloma research staff.
For cutaneous T cell lymphomas, please refer to additional procedures in protocol PA18-0191 and Appendix 13.

Protocol 2014-0630
November 13, 2018
 
 
58
APPENDIX 2
 
Revised Response Criteria for Malignant Lymphoma
 
Response
Definition
Nodal Masses
Spleen, Liver
Bone Marrow
 
 
CR
 
 
Disappearance of all
evidence of disease
(a) FDG-avid or PET positive prior to
therapy; mass of any size permitted if PET
negative (b) Variably FDG-avid or PET
negative; regression to normal size on CT
 
 
Not palpable, nodules 
disappeared
Infiltrate cleared on repeat biopsy;
if indeterminate by morphology,
immunohistochemistry should be 
negative
 
 
 
 
PR
 
 
 
Regression of 
measurable disease
and no new sites
 50% decrease in SPD of up to 6 largest 
dominant masses; no increase in size of
other nodes (a) FDG-avid or PET positive
prior to therapy; one or more PET positive
at previously involved site (b) Variably 
FDG-avid or PET negative; regression on 
CT
 
 50% decrease in SPD
of nodules (for single
nodule in greatest 
transverse diameter);
no increase in size of 
liver or spleen
 
 
 
Irrelevant if positive prior to
therapy; cell type should be
specified
 
 
SD
 
Failure to attain 
CR/PR or PD
(a) FDG-avid or PET positive prior to
therapy; PET positive at prior sites of 
disease and no new sites on CT or PET
 
 
 
 
(b) Variably FDG-avid or PET negative; no
change in size of previous lesions on CT
 
 
 
Relapsed 
disease or 
PD
 
Any new lesion or 
increase by  50% of
previously involved 
sites from nadir
Appearance of a new lesion(s) > 1.5 cm in
any axis,  50% increase in SPD of more 
than one node, or  50% increase in longest 
diameter of a previously identified node > 1
cm in short axis
 
> 50% increase from 
nadir in the SPD of any 
previous lesions
 
 
 
New or recurrent involvement
 
 
Lesions PET positive if FDG-avid
lymphoma or PET positive prior to therapy
 
 
 
Abbreviations: CR, complete remission; FDG, [18F]fluorodeoxyglucose; PET, positron emission tomography; CT, computed tomography; PR, partial
remission; SPD, sum of the product of the diameters; SD, stable disease; PD, progressive disease.

Protocol 2014-0630
November 13, 2018
 
 
59 
APPENDIX 3
 
ECOG PERFORMANCE STATUS
 
 
 
 
Grade 
 
Description 
 
0 
 
Normal activity, fully active, able to carry on all pre-disease 
performance without restriction. 
 
1 
 
Symptoms, but fully ambulatory, restricted in physically strenuous 
but ambulatory and able to carry out work of a light or sedentary 
nature (e.g., light housework, office work). 
 
2 
 
Ambulatory and capable of all self-care but unable to carry out any 
work activities.  Up and about more than 50% of waking hours. 
 
3 
 
Capable of only limited self-care, confined to bed or chair more than 
50% of waking hours. 
 
4 
 
Completely disabled. Cannot carry on any self-care. Totally confined 
to bed or chair. 
 
5 
 
Dead 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol 2014-0630
November 13, 2018
 
 
60 
APPENDIX 4
 
NCI CTCAE Version 4.03
 
 
 
Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI)
v4.03
 
 
 
 
Publish Date: June 14, 2010
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
 
 
 

Protocol 2014-0630
November 13, 2018
 
 
61 
Appendix 5.
Modified ISCL/EORTC Revisions to the TNMB Classification of MF/SS1
TNMB Stages
Description of TNMB
Skin*
T1
Limited patches, papules, and/or plaques covering < 10% of the skin surface; may further stratify into T1a (patch only) v T1b
(plaque ± patch)
T2
3DWFKHVSDSXOHVRUSODTXHVFRYHULQJRIWKHVNLQVXUIDFHPD\IXUWKHUVWUDWLI\LQWR72a (patch only) v T2b (plaque ± patch)
T3
2QHRUPRUHWXPRUVFPGLDPHWHU
T4
&RQIOXHQFHRIHU\WKHPDFRYHULQJERG\VXUIDFHDUHD
Node†
N0
No clinically abnormal lymph nodes; biopsy not required
N1
Clinically abnormal lymph nodes; histopathology Dutch grade 1 or NCI LN0-2
N1a
Clone negative
N1b
Clone positive

Protocol 2014-0630
November 13, 2018
 
 
62 
TNMB Stages
Description of TNMB
N2
Clinically abnormal lymph nodes; histopathology Dutch Grade 2 or NCI LN3
N2a
Clone negative
N2b
Clone positive
N3
Clinically abnormal lymph nodes; histopathology Dutch grade 3-4 or NCI LN4; clone positive or negative
Nx
Clinically abnormal lymph nodes without histologic confirmation or inability to fully characterize the histologic subcategories
Visceral
M0
No visceral organ involvement
M1
Visceral involvement (must have pathology confirmation and organ involved should be specified)
Blood
B0
Absence of signifLFDQWEORRGLQYROYHPHQWRISHULSKHUDOEORRGO\PSKRF\WHVDUHDW\SLFDO6p]DU\FHOOV
B0a
Clone negative

Protocol 2014-0630
November 13, 2018
 
 
63 
TNMB Stages
Description of TNMB
B0b
Clone positive
B1
Low blood tumor burden: > 5% of peripheral blood lymphocytes are atypical (Sézary) cells but does not meet the criteria of B2
B1a
Clone negative
B1b
Clone positive
B2
+LJKEORRGWXPRUEXUGHQȝ/6p]DU\FHOOVZLWKSRVLWLYHFORQH‡; one of the following can be substituted for Sézary cells: 
&'&'&'&'- FHOOVRU&'&'- FHOOV
Abbreviations: ISCL, International Society for Cutaneous Lymphomas; EORTC, European Organisation for Research and Treatment 
of Cancer; MF, mycosis fungoides; SS, Sézary syndrome; NCI, National Cancer Institute.
*Patch = any size lesion without induration or significant elevation above the surrounding uninvolved skin: pokiloderma may be
present. Plaque = any size lesion that is elevated or indurated: crusting or poikiloderma may be present. Tumor = any solid or 
QRGXODUOHVLRQFPLQGLDPHWHUZLWKHYLGHQFHRIGHHSLQILOWUDWLRQLQWKHVNLQDQGRUYHUWLFDOJURZWK
†Lymph node classification has been modified from 2007 ISCL/EORTC consensus revisions1 to include central nodes. Lymph nodes 
are qualified as abnormal if > 1.5 cm in diameter.
‡The clone in the blood should match that of the skin. The relevance of an isolated clone in the blood 
 

Protocol 2014-0630
November 13, 2018
 
 
64 
Appendix 6
Response in Skin
Response
Definition
Complete response
100% clearance of skin lesions*
Partial response
50%-99% clearance of skin disease from baseline without new tumors (T3) in patients with T1, T2 or T4 only skin disease
Stable disease
< 25% increase to < 50% clearance in skin disease from baseline without new tumors (T3) in patients with T1, T2, or T4 only 
skin disease
Progressive 
disease†
LQFUHDVHLQVNLQGLVHDVHIURPEDVHOLQHRU
New tumors (T3) in patients with T1, T2 or T4 only skin disease or
Loss of response: in those with complete or partial response, increase of skin score of greater than the sum of nadir plus 
50% baseline score
Relapse
Any disease recurrence in those with complete response
NOTE. Based on modified Severity Weighted Assessment Tool score.
*A biopsy of normal appearing skin is unnecessary to assign a complete response. However, a skin biopsy should be performed of a 
representative area of the skin if there is any question of residual disease (persistent erythema or pigmentary change) where
otherwise a complete response would exist. If histologic features are suspicious or suggestive of mycosis fungoides/Sézary
syndrome (see histologic criteria for early mycosis fungoides7), the response should be considered a partial response only.
†Whichever criterion occurs first.
Olsen E. Vonderheid E.,  ,Pimpinell N, et al Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a 
proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European 
Organization of Research and Treatment of Cancer (EORT). Blood. 2007: 110(6) 1713-1722 

Protocol 2014-0630
November 13, 2018
 
 
65 
Appendix 7
Response in Lymph Nodes*
Response
Definition
CR
$OOO\PSKQRGHVDUHQRZFPLQJUHDWHVWWUDQVYHUVHORQJD[LVGLDPHWHUE\PHWKRGXVHGWRDVVHVVO\PSKQRGHVDWEDVHOLQH or 
biopsy negative for lymphoma; in addition, lymph nodes that were N3 FODVVLILFDWLRQDQGFPLQWKHLUORQJD[LVDQG!FPLn their 
VKRUWD[LVDWEDVHOLQHPXVWQRZEHFPLQWKHLUVKRUWD[LVRUELRSV\QHJDWLYHIRUO\PSKRPD
PR
&XPXODWLYHUHGXFWLRQRIWKH63'RIHDFKDEQRUPDOO\PSKQRGHDWEDVHOLQHDQGQRQHZO\PSKQRGH!FPLQWKHGLDPHWHUof 
the long axis or > 1.0 cm in the diameter of the short axis if the long axis is 1-1.5 cm diameter
SD
Fails to attain the criteria for CR, PR, and PD
PD†
LQFUHDVH in SPD from baseline of lymph nodes or
Any new node > 1.5 cm in the long axis or > 1 cm in the short axis if 1-1.5 cm in the long axis that is proven to be N3 histologically or
Loss of response: > 50% increase from nadir in SPD of lymph nodes in those with PR
Relapse
Any new lymph node > 1.5 cm in the long axis in those with CR proven to be N3 histologically
Abbreviations: CR, complete response; PR, partial response; SPD, sum of the maximum linear dimension (major axis) × longest 
perpendicular dimension (minor axis); SD, stable disease; PD, progressive disease.
*Peripheral and central lymph nodes.
†Whichever criterion occurs first.
 
 

Protocol 2014-0630
November 13, 2018
 
 
66 
Appendix 8
Response in Blood*
Response
Definition
CR†
B0
PR‡
> 50% decrease in quantitative measurements of blood tumor burden from baseline in those with high tumor burden at baseline (B2)
SD
Fails to attain criteria for CR, PR, or PD
PD§
B0 to B2 or
!LQFUHDVHIURPEDVHOLQHDQGDWOHDVWQHRSODVWLFFHOOVȝ/36 or
Loss of response: in those with PR who were originally B2 at baseline, > 50% increase from nadir and at least 5,000 neoplastic 
FHOOVȝ/
Relapse
,QFUHDVHRIQHRSODVWLFEORRGO\PSKRF\WHVWR%1 in those with CR
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
*$VGHWHUPLQHGE\DEVROXWHQXPEHUVRIQHRSODVWLFFHOOVȝ/
†If a bone marrow biopsy was performed at baseline and determined to unequivocally be indicative of lymphomatous involvement, 
then to confirm a global CR where blood assessment now meets criteria for B0, a repeat bone marrow biopsy must show no residual 
disease or the response should be considered a PR only.
‡There is no PR in those with B1 disease at baseline as the difference within the range of neoplastic cells that define B1 is not 
considered significant and should not affect determination of global objective response.
§Whichever occurs first.
 
 

Protocol 2014-0630
November 13, 2018
 
 
67 
Appendix 9
 
Response in Viscera
Response
Definition
CR
Liver or spleen or any organ considered involved at baseline should not be enlarged on 
physical exam and should be considered normal by imaging; no nodules should be present 
on imaging of liver or spleen; any post treatment mass must be determined by biopsy to be 
negative for lymphoma
PR
UHJUHVVLRQLQDQy splenic or liver nodules, or in measureable disease (SPD) in any 
organs abnormal at baseline; no increase in size of liver or spleen and no new sites of 
involvement
SD
Fails to attain the criteria for CR, PR, or PD
PD*
> 50% increase in size (SPD) of any organs involved at baseline or
New organ involvement or
Loss of response: > 50% increase from nadir in the size (SPD) of any previous organ 
involvement in those with PR
Relapse
New organ involvement in those with CR
Abbreviations: CR, complete response; PR, partial response; SPD, sum of the maximum linear dimension (major axis) × 
longest perpendicular dimension (minor axis); SD, stable disease; PD, progressive disease.
*Whichever criterion occurs first
 

Protocol 2014-0630
November 13, 2018
 
 
68 
Appendix 10
Skin Assessment and Scoring
NOTE. mSWAT score equals summation of total patch, plaque and tumor
Abbreviations: BSA, body surface area; mSWAT, modified Severity Weighted Assessment Tool.
Patch-Any size lesion without induration or significant elevation above the surrounding uninvolved skin; poikiloderma may 
be present. Total sum is multiplied by 1 for mSWAT (modified Severity Weighted Assessment Tool)
Plaque Any size lesion that is elevated or indurated; crusting, ulceration, or poikiloderma may be present. Total sum is 
multiplied by 2 for mSWAT
Tumor ‡$Q\VROLGRUQRGXODUOHVLRQFPLQGLDPHWHUZLWKHYLGHQFHRIGHHSLQILOWUDWLRQLQWKHVNLQDQGRUYHUWLFDOJURZWK
Total sum is multiplied by 4 for mSWAT.
 

Protocol 2014-0630
November 13, 2018
69 
Appendix 11  Body Surface Area Assessment Note

Protocol 2014-0630
November 13, 2018
 
 
70 
Appendix 12 CTCL Assessment and Response
 
 Response criteria for patients with CTCL will be determined from the composite scores (Global 
Response) of four categories – skin, nodes, visceral and blood (Appendix 5-9) the criteria for response 
and staging is from ISCL/EORTC recommendation (Olsen, 2011).Skin assessment is done by modified 
skin weighted assessment tool(Appendix 10 & 11). Node and visceral assessment is determined by CT 
scan. A node biopsy at screening will be done on patients with nodes> 1.5 cm and clinically suspicious for 
disease. Blood is assessed by peripheral blood flow cytometry.
1)
Complete Response (CR) is the complete absence of all clinical disease in all involved categories
2)
Partial response skin (PR) is either CR or PR and
a.
All categories do not have a CR or not involved (NI) and no category has progressive 
disease or
b.
No category has progressive disease (PD) and if any category is involved at baseline, at 
least  one has a CR or PR
3)
Stable disease skin (SD) is either PR or SD
a.
No category has progressive disease and if any category is involved at baseline, no CR 
or PR
b.
CR/NI/PR/SD in any category and no category has PD
4)
Progressive disease is PD in any category
5)
Relapse-recurrence disease in prior CR is relapse in any category

Protocol 2014-0630
November 13, 2018
 
 
71 
APPENDIX 13
Table of Assessments for Cutaneous T-Cell Lymphoma
Study visits and procedures 
may be scheduled with a +/-
3 business day window
Screening
Cycle 1 (D1 – 21)
Cycle 2+
End of Treatment
Follow-
up
Within 28 
days*
Day 1
Day 2
Day 8
Day 9
Day 15
Day 16
Day 1
Day 2
30 ( +/- 3) days 
post last dose)17
Medical RX history1
X
Physical exam, ECOG, Height
X
X
(X)2
(X)2
X2
X
Vital signs3
X
X
X
X
X
X
Neurologic assessment4
X
X
X
X
12-lead ECG14
X
X14
X14
X14
X
Hematology5
X
X
X
X
X
X
Full serum chemistries6
X
X
X
X
X
X
Coagulation test7
X
X
Pregnancy test8
X
X
CT chest/abd/pelvis/neck
X
X22
X
CXR
X
X
mSWAT
X
X
X23
X
Peripheral blood flow 
cytometry
X
X24
X
Photographs
X
X23
X
Pruritus
X
X
X23
X
ONC 201 administration13
X
X
X
Blood sample for PK
X15
X
X
Optional blood/tissue samples 
for Correlative studies
X
X25
X
Adverse events
X
X
X
X
X
X
X
X
X
Concomitant medications
X
X
X
X
X
X
X
X
X
Disease status and survival
X18
MDASI21
X
X
X
X
X
X
X21
Parentheses indicate that the particular test is situational at that time point, as specified in the respective footnote. 
* All laboratory assessments are to be done with 14 days of first day of study drug administration, unless otherwise noted. 
1. Medical history: prior treatments for lymphoma, significant medical conditions, neuropathy history. 
2. Physical examination: review of systems, height at baseline, weight, and if significant weight loss or gain (+/- 10%). Abbreviated PE on Days 8 and 15 of Cycle 1 and Days 1 of each 
cycle or as clinically indicated. 
3. Vital signs: systolic and diastolic blood pressure, respiration, pulse, oral temperature prior to dosing. 
4. Neurologic exam: evaluate peripheral neuropathy and/or changes in preexisting neuropathy. 
5. Hematology: hemoglobin, hematocrit, WBC with complete manual differential (neutrophils [segmented and bands], lymphocytes, monocytes, eosinophils, basophils), RBCs, platelet 
count (For Day 1, screening panel may be used if within 24 hours prior to initiation of therapy). Obtain and review on Day 1 of all cycles prior to each dose of ONC 201, on Days 8 
and 15 of Cycle 1, and as clinically indicated. 

Protocol 2014-0630
November 13, 2018
 
 
72 
6. Full blood chemistry panel: BUN, creatinine, glucose, uric acid, bicarbonate, calcium, chloride, phosphorus, potassium, sodium, albumin, total protein, magnesium, total bilirubin, 
alkaline phosphatase, ALT, AST, LDH (for Day 1 screening panel may be used if within 24 hours prior to starting treatment). Obtain and review prior to each dose of ONC201 on 
'D\RIHDFKVXEVHTXHQWF\FOHRQ'D\VDQGRI&\FOHDQGDVFOLQLFDOO\LQGLFDWHG6HUXPȕPLFURJOREXOLQYLUDOKHSDWitis panel including HBsAg, HBcore antibody, HB 
antibody, Hep C antibody, and GGT at baseline. 
7. Coagulation tests: prothrombin time, activated partial thromboplastin time, and international normalized ratio (historical panel may be used if within 14 days prior to starting treatment) 
1st day of study drug 
8. Pregnancy Test –urine or serum in women of child bearing potential. If a menstrual period in a treated woman does not occur at the anticipated timing a pregnancy test should be 
performed. A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally 
postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). 
9. Disease Assessment every other cycle beginning on cycle 3 (i.e. every odd cycle): Obtain bi-dimensional measurements when measurable disease is present unless it becomes PET 
negative (see response assessment criteria in Appendix 2). Either a PET/CT or a CT can be used before and/or after treatment to assess response. 
10. Repeat every other cycle beginning on cycle 3 (i.e. every odd cycle) for the duration of treatment. Perform only those evaluations with known or suspected sites of disease. If no 
change in persistent mass, a biopsy is to be performed, if feasible. 
11. Send baseline bone marrow aspirate for cytogenetics and lymphoma markers. FISH for IgH/cyclin D1 may be required to make a definitive diagnosis if bone marrow is inconclusive. 
Repeat only if initially positive and send bone marrow aspirate for lymphoma markers. Repeat bone marrow biopsy to confirm CR. 
12. Baseline colonoscopy and other GI endoscopies are required only if this is the main area of disease response assessment. If in CR by radiologic evaluation, bone marrow or blood test 
at any time, do colonoscopy with random biopsy and bone marrow biopsy and PET scan if necessary and possible to confirm CR. 
13. ONC201 administration: See Section 4 for study drug administration and Section 6.2 for dose modification guidelines. 
14. ECG: baseline, Cycle 1 Day 1 (15 minutes ± 10 minutes, 1 hour ± 15 minutes, and 2 hours ± 30 minutes post-dose), Cycle 1 day 2, Cycle 1 Day 8, and when patients come off study. 
If indicated due to any cardiac abnormalities, two additional ECGs must be performed at intervals approximately 3 minutes apart. 
15. Blood draws taken at baseline, 30 ± 15 minutes, 2 hours ± 30 minutes, 4 hours ± 30 minutes, 6 hours ± 30 minutes, 24 ± 1 hour , 48 hours ± 12 hours, 72 ± 12 hours, 96 ± 12 hours, 
and 168 hours ± 24 hours following administration in the first cycle. 
16. Blood draws taken at baseline, 24 ± 1 hour, 48 hours ± 12 hours, and 168 hours ± 24 hours following administration in the first cycle. PD samples can be collected in parallel to PK 
samples. Each PD blood draw will include one EDTA tube and one tube without anticoagulant. 
17. Approximately 30 days (+/- 3) after discontinuation of all study drugs or before start of subsequent treatment (whichever occurs first). 
18. Every 3 months via telephone for all subjects for 1 year. 
19. For patients with measurable disease, optional core tumor biopsy will be collected at Screening for correlative studies. If patient has had a core biopsy within 12 months, a formalin-
fixed paraffin embedded tumor block or slides may be used instead. See Section 7.1.7 for correlative studies to be run.
20. Blood draws taken pre-dose for Cycle 2 and beyond. PD samples can be collected in parallel to PK samples. Tissue samples will be taken at re-staging, as clinically indicated (See 
footnote 10.) 
21. Patients will complete the MDASI starting at screening and weekly until the start of therapy. The MDASI will then be completed weekly beginning on the day after the first dose of
study drug for the first 3 cycles of therapy (C1D2, C1D9, C1D16, C2D2, C2D9, C2D16, C3D2, C3D9, C3D16). Patients will then complete the MDASI the day after the start of each 
cycle of therapy (C4+D2) and approximately 30 days (+/- 3 days) after discontinuation of study drug or before the start of subsequent treatment (whichever occurs first). In follow up, 
patients will complete the MDASI every 3 months for 1 year. MDASI assessments may be completed on paper or electronic tablet when the patient is in clinic. When the patient is at 
home, the MDASI can be completed by Interactive Voice Response (IVR) automated telephone system, electronically through email, or by personal phone call with research staff. 
Patients have the discretion to elect to forego completion of the MDASI at any time point. All data will be stored in the Department of Lymphoma/Myeloma. MDASI data collection 
quality and completeness will be monitored by Department of Lymphoma/Myeloma research staff. 
22 Repeat every third cycle of therapy beginning at Cycle 4 for patients N2 and N3 at screening. Patients < N2 within 1 week of first skin response or to confirm progression in nodes.
23 mSWAT, Photographs and Pruritus at each Day 1. 
24 Repeat every third cycle beginning at Cycle 4 for those patients B1 or B2 at screening 
25 Optional skin biopsy and blood at Cycle 2 Day 1 pre-dose

Protocol 2014-0630
November 13, 2018
 
 
73 
11. REFERENCES
 
Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, et al. Dual inactivation of Akt and
ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction and potent anti-tumor
effects. Science Translational Medicine. 2013.
 
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of
lymphoid
neoplasms
and
beyond:
evolving
concepts
and
practical
applications.
Blood
117(19):5019–5032, 2011.
 
Cheson BD, Horning SJ, Coiffier
B, et al. Hematologic Oncology: Report of an International
Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. JCO 1244, 1999.
 
Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JHF, et al. Combined
inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase 
pathways results in synergistic effects in glioblastoma cells. Molecular Cancer Therapeutics 
5(3):645-54, 2006.
 
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of
Cancer 45(2):228-47, 2009.
 
Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A ,et
al. Multicenter phase II study of bortezomib in patients with relapsed or refractory, 2006.
 
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a
Standard Regimen (CHOP) with three intensive chemotherapy regimens for advanced non-
Hodgkin’s Lymphoma N Engl J Med 328:1002-6, 1993.
 
Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, Pott C, Seymour JF, et al. 
Maintenance therapy with rituximab leads to a significant prolongation of response duration after
salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone
(R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a
prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 
108(13):4003–4008, 2006.
 
Goodsell DS. The Molecular Perspective: The ras Oncogene. The Oncologist 4(3):263-4, 1999.
 
Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, et al. 
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event 
analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20(3): 520-5, 2009.
 
Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, et al. Age-adjusted
International Prognostic Index predicts autologous stem cell transplantation outcome for patients
with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102:1989-96, 2003.
 
He L, Jang JH, Choi HG, Lee SM, Nan MH, Jeong SJ, Dong Z, Kwon YT, Lee KS, Lee KW, Chung 

Protocol 2014-0630
November 13, 2018
 
 
74 
JK, Ahn JS, Kim BY. Oligomycin A enhances apoptotic effect of TRAIL through CHOP-mediated 
death receptor 5 expression. Mol Carcinog. 2013 Feb; 52(2):85-93.
 
Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner
R, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 
27(4):511–518, 2009.
 
Hiddemann W, Unterhalt M, Herrmann R, Woltjen HH, Kreuser ED, Trumper L, Reuss-Borst M, 
Terhardt-Kasten E, et al. Mantle-cell lymphomas have more widespread disease and a slower response
to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative
analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 16(5):1922– 1930, 1998.
 
Ishizawa J and Andreeff M, unpublished data, 2014.
 
Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma:
perspectives for new targeted therapeutics. Nat Rev Cancer 7(10):750–762, 2007.
 
Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, et al. 
Maintenance rituximab following induction chemoimmunotherapy may prolong progression free
survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol
17(9):1418–1423, 2006.
Kahl BS1, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016 Apr 
28;127(17):2055-63.
 
Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as
second-line therapy before autologous stem cell transplantation for relapsed or primary refractory
diffuse large B-cell lymphoma. Blood 103:3684-8, 2004.
 
Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, et
al. Concurrent administration of high-dose rituximab before and after autologous stem-cell
transplantation
for
relapsed
aggressive
B-cell
non-Hodgkin’s
lymphomas.
J
Clin
Oncol 
23(10):2240–2247, 2005.
 
Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, et al. Nonablative 
allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 
21(23):4407–4412, 2003.
 
Komatsu S, Miyazawa K, Moriya S, Takase A, Naito M, Inazu M, Kohno N, Itoh M, Tomoda A.
Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-
mediated CHOP (GADD153) induction and autophagy in breast cancer cells. Int J Oncol. 2012 Apr;
40(4):1029-39.
 
 
Leonard JP, Schattner EJ, Coleman M. Biology and management of mantle cell lymphoma. Curr
Opin Oncol 13(5):342–347, 2001.
 
Li H, Chang G, Wang J, Wang L, Jin W, Lin Y, Yan Y, Wang R, Gao W, Ma L, Li Q, Pang T.
Cariporide Sensitizes Leukemic Cells to TRAIL by Up-regulation of Death Receptor 5 via ER

Protocol 2014-0630
November 13, 2018
 
 
75 
stress-CHOP dependent Mechanism. Leuk Lymphoma. 2013 Nov 4.
 
 
Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, et al. R-ESHAP as salvage 
therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior 
exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 93:1829-36, 2008.
 
Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P et al. Intensive 
treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival
exceeding 7 years with standard therapies. Ann Oncol
19(7):1327–1330, 2008.
 
Perry AR, Goldstone AH. High-dose therapy for diffuse large-cell lymphoma in ¿rst remission. Ann
Oncol 9:1:9-14, 1998.
 
Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like 
chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-
prognosis diffuse large-B-cell lymphoma: A randomized controlled trial by the MabThera
International Trial (MInT) Group.
Lancet Oncol 7:379-91, 2006.
 
Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, 
Younes A, et al. High rate of durable remissions after treatment of newly diagnosed aggressive
mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose 
methotrexate and cytarabine. J Clin Oncol 23(28):7013–7023, 2005.
 
Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan
TM, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic 
events that predicts survival in mantle cell lymphoma. Cancer Cell 3(2):185–197, 2003.
 
Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, Song JY, Woroniecka R, et
al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell
lymphoma. Blood 121(8): 1394-402, 2013.
 
Senderowicz AM. Information Needed to Conduct First-in-Human Oncology Trials in the United
States: A View from a Former FDA Medical Reviewer. Clinical Cancer Research. 2010 March 15,
2010;16(6):1719-25.
 
Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, et al. The Clinical
Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways
in Patients with Advanced Cancer. Clinical Cancer Research. 2012 April 15, 2012;18(8):2316-25.
 
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO
classification of tumours of haemotopoietic and lymphoid tissues, 4th edn. WHO Press, Geneva
(Switzerland), 2008.
 
 
Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials 
with multiple outcomes. Stat Med 14(4):357-379, 1995. PMID: 7746977.

Protocol 2014-0630
November 13, 2018
 
 
76 
 
Vellenga E, van Putten WL, van't, Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, et al. Rituximab
improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive 
CD20+NHL: A prospective randomized HOVON trial. Blood 111:537-43, 2008.
 
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with Ibrutinib in 
Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 369:507-516, 2013.
 
Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma: a follicular variant of 
intermediate lymphocytic lymphoma. Cancer 49(7):1429–1438, 1982.
 
Yang J-Y, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by
inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10(2):138-48.
 
Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, Kwak L, Yi Q, et al. Incidence
trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113(4):791–
798, 2008.